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CHAPTER I 
 
Pancreatic ductal adenocarcinoma (PDAC) 
Pancreatic cancer is a neoplastic malignant disease characterized by atypical growth of cells in 
the pancreas, a glandular organ that is part of the digestive system and endocrine system. The 
pancreas composed by two different tissues with distinct functions: the exocrine tissue, which is 
dedicated to the secretion of the enzymes into the digestive tract, helping the digestions of 
carbohydrates, lipids and proteins; and the endocrine tissue, which produces and release into the 
blood stream several hormones, including glucagon, insulin and somatostatin. The most common 
type of pancreatic cancer, accounting for 95% of these tumors, is pancreatic ductal 
adenocarcinoma (PDAC), which derives from the exocrine component of the pancreas. The 
remaining 5% originate from islet cells and are classified as neuroendocrine tumors.  
PDAC is a common cause of death among solid cancers worldwide (Ferlay J et al., 2010; 
Siegel R et al., 2012), representing one of the most lethal malignancies. This poor outcome is 
due to late diagnosis, which often occurs when the disease is locally advanced or metastatic, thus 
excluding almost any possibility of a curative resection. Moreover, PDAC is an aggressive 
tumour and displays resistance to current medical treatment, resulting in rapidly spreading and 
metastatic disease (Vincent A et al., 2011). The median survival period is extremely low 
(Cunningham D et al., 2009; Stathis A and Moore MJ, 2010), emphasizing the need for 
improvement in diagnosis and treatment of this disease. 
 
1.1 Molecular characteristics of PDAC carcinogenesis 
 
The development of PDAC is a stepwise process, involving accumulation of genetic mutations 
that results in a gain of cell growth, proliferation, and metastatic dissemination. Non-invasive 
stages of duct lesions have been identified in PDAC preceding invasive carcinoma (Singh M and 
Maitra A, 2007). The three main premalignant epithelial lesions recognized are pancreatic 
intraepithelial neoplasia (PanIN), mucinous cystic neoplasia (MCN), and intraductal pancreatic 
mucinous neoplasia (IPMN). PanIN lesions can be classified in four grades, based on the degree 
of dysplasia reflected in cytonuclear atypia and architectural change: PanIN-1A, PanIN-1B, 
PanIN-2, and PanIN-3. PanIN-3 lesions also known as carcinoma-in-situ, own all of the 
characteristics of cancer, like loss of cell polarity, atypical nuclei, frequent mitoses and budding 
of neoplastic cells in the lumen. However, the growth of the premalignant lesion is non invasive 
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and remains confined within the basement membrane (Hruban RH et al., 2004). The increasing 
grade of dysplasia of the PanIN lesions manifests the morphological steps that precedes invasive 
PDAC and are genetically accompanied by genetic alterations in tumor suppressor genes, 
oncogenes and genes involved in the maintenance of genome stability. An early event in PDAC 
development is the mutation of the KRAS2 oncogene which is found mutated in 20% of PanIN-1 
lesions and this percentage increases with PDAC until 95%. Other genetics alterations concern 
HER-2/neu, p16, p53, SMAD4, cyclin D1, Ki-67 and BRCA2 genes, indicating that they are 
involved in the evolution from preneoplastic to infiltrating ductal carcinoma (Feldmann G et al., 
2007). (Fig 1).  
 
 
 
Figure 1: Progression model of PDAC from normal duct to invasive cancer. 
The morphological evolution of the neoplasia correlates with the progressive accumulation of specific genetic 
alterations, highlighted below the pictures. (Ottenhof NA et al., 2011) 
 
Screening of PDAC samples revealed the alterations of five major pathways involved in crucial 
cellular functions: apoptosis, repair of DNA damage, G1/S phase cell cycle progression, cell 
adhesion and invasion (Jones S et al., 2008). Despite the increasing evidence that underline the 
involvement of epigenetics changes (Omura N et al., 2009) and alteration of microRNA 
expression (Szafranska AE et al., 2008) in pancreatic carcinogenesis, the hallmark mutations that 
describe advanced pancreatic intraepithelial neoplasias and invasive carcinomas remain the 
constitutive activation of KRAS2 oncogene and the inactivation or deletion of the p53 and 
SMAD4 tumor suppression genes (Ottenhof NA et al., 2011). 
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1.2 Symptoms and risk factors 
 
Early stages of PDAC are usually clinically silent and the symptoms emerge only when the 
cancer has advanced to a late stage. Typical initial symptoms are abdominal pain, weight loss 
caused by difficulty in digestion and problems with sugar metabolism. Moreover, as the tumour 
grows, its mass may block the bile duct, leading to an accumulation of bilirubin in the blood and 
causing obstructive jaundice. 
The etiology of PDAC is still unknown, even though numerous risk factors have been identified, 
including smoking, alcohol assumption, family history of chronic pancreatitis and pancreatic 
cancer, advancing age, male sex, diabetes mellitus and central obesity (abdominal obesity), 
(Zheng W et al., 1993). Diet also contributes to cancer risk, in particular the assumption of 
animal products rich in red meat, while consumption of vegetables and fruits has been suggested 
as preventive measure. Some genetic syndromes are been described as risk factors for PDAC as 
Peutz-Jeghers syndrome, familial atypical multiple mole melanoma, ataxia-telangiectasia and 
hereditary nonpolyposis colon cancer.  
 
1.3 Diagnosis and prognosis 
 
The analysis of pancreatic and liver functions may indicate a possible PDAC, combined with the 
analysis of the level of CA19-9 (carbohydrate antigen 19.9), a marker that is frequently elevated 
in pancreatic cancer. To construct a diagnosis and to establish the stage of the disease, multiple 
imaging techniques can be used to identify the location, the form and the stage of the PDAC. As 
first line approach, ultrasonography is the diagnostic method most frequently used to search liver 
alterations while the best initial diagnostic test for pancreatic cancer is computed 
tomography (CT) scan. Nonetheless, the accuracy of this screening is only about 65% for the 
lesions up to 2 cm in diameter. Additional  imaging techniques can be used to determine possible 
obstructions of bile ducts and levels of the spreading of the cancer. In order to obtain accurate 
diagnosis, endoscopic ultrasound is performed, allowing the identification of small neoplastic 
lesions. This technique is accompanied by a needle biopsy to examine pancreatic cells for signs 
of cancer, increasing the diagnostic sensitivity up to 80%. However, these procedures still 
remain vary invasive and bring about risks of developing complications. Positron Emission 
Tomography/Computed Tomography (PET/CT) is not currently part of routine staging but can 
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be helpful for the identification of metastatic disease. The early diagnosis of PDAC could be 
crucial for the cure of the patients, thus searching for innovative markers detectable in 
bloodstream or biopsy is currently ongoing  (McCarthy DM et al., 2003).  
After diagnosis, the stage of PDAC is determined on the basis of the cancer progression: there 
are currently four different stages that describes cancer size, lymph node invasion, metastasis and 
clinical criteria (Varadhachary GR et al., 2006). Stage I are the local and resectable cancers, 
confined to the pancreas and not spread to other tissues, with a median survival period of 17/23 
months. Stage II cancers have spread locally with signs of vascularization without reaching the 
lymph nodes or other tissues, with a median survival period up to 20 months. Currently, the 
clinical approach of this stage consists in a radiochemotherapy treatment in order to evaluate if 
cancer may regress to a resectable state. Stage III are the locally advanced or unresectable 
cancer, which have reached the lymph nodes but have not invaded other tissues whereas the 
stage IV presents with metastasis. The median survival period is 8–14 months for the stage III 
and decreases to 4–6 months for the stage IV, with no possibility of surgery. 
 
1.4 Treatment  
 
First line approach to treat PDAC is surgical resection whenever the cancer is confined to 
pancreas. However, this treatment is reserved to very few cases, due to the surgery-related 
complications. When cancer is spread to surrounding tissues or in metastasis, therapeutic 
approaches are aimed to solve the complication caused by the disease (Wray CJ et al., 2005). 
After surgery, adjuvant radiotherapy or chemotherapy has been shown in several large 
randomized studies to significantly increase the median survival period from approximately 10 
to 20%. Chemotherapy is generally used if PDAC is spread and surgery is not suitable for 
intervention. In this case, palliative chemotherapy may be used to improve quality of life and to 
obtain a modest survival benefit. Gemcitabine represents the currently standard therapy for 
patients with advanced pancreatic cancer alone or in combination with other compounds (Burris 
HA 3rd et al., 1997; Storniolo AM et al., 1999), can induce a partial response and can alleviate 
symptoms due to advanced tumours.  
Gemcitabine is a nucleoside analog that replaces one of the nucleic acids (cytidine) during DNA 
replication and it is incorporate into DNA chain. Thus, cancer cells are exposed to a genotoxic 
stress that arrest tumour growth and cause apoptotic cell death. However, significant results in 
improvement of survival have not been achieved due to the development of escape pathways that 
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lead to chemoresistance. Understanding the mechanisms of genotoxic stress resistance and 
discovery of new therapeutic targets is therefore of clinical importance. 
 
1.5 Role of Epithelial to mesenchymal transition in PDAC 
 
The Epithelial to Mesenchymal Transition (EMT) is a developmental process that allows 
polarized epithelial cells to undergo multiple changes that enable them to assume a mesenchymal 
phenotype, characterized by enhanced migratory ability, invasiveness and elevated resistance to 
apoptosis (Kalluri R et al; 2003). It is possible to distinguish epithelial from mesenchymal cells 
by analyzing specific markers. The epithelial cells are characterized by the expression of a cohort 
of specific proteins, among which are cytoskeletal proteins (i.e. E-cadherin, cytokeratin; Lee JM 
et al; 2006, Kalluri R et al; 2003) and epithelial specific RNA binding proteins (i.e. ESRP1, 
ESRP2; Warzecha CC et al, 2009; Horiguchi K et al., 2011). On the contrary, mesenchymal 
cells are characterized by expression of vimentin and fibronectin  (Lee JM et al; 2006, Kalluri R 
et al; 2003) and of specific transcription factors that directly or indirectly inhibit the expression 
of E-cadherin (i.e. SLUG, SNAIL, ZEB1, ZEB2; Lee JM et al; 2006, Kalluri R et al; 2003) (Fig 
2). 
 
Figure 2: Schematic illustration of EMT rearrangements 
Epithelial cells undergo multiple changes that cause their transformation from cobblestone, non invasive and 
chemosensitive cells to spindle-like, invasive and chemoresistant cells. Principal specific epithelial or mesenchymal 
markers are indicated. 
 
The EMT process comprises deep rearrangements in gene expression resulting in a finely 
regulated circuit that involves multiple layers: regulation of gene expression mediated by 
specific transcription factors (Thiery JP et al., 2009), regulation of alternative splicing (De 
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Craene B et al., 2013; Warzecha CC and Carstens RP, 2012) and microRNA regulation (Gregory 
PA et al., 2008; Cano A and Nieto MA, 2008.). 
Neoplastic cells may undergo EMT, thus becoming invasive cells that can promote the onset of 
metastasis (Thiery JP., 2002). Indeed, spindle-like cells are typically seen at the invasive front of 
primary tumors and are considered to be responsible for cancer colonization (Thiery JP., 2002; 
2009). Moreover, it has been demonstrated that multiple EMT regulators have the ability to 
enhance tumor formation and/or metastasis (Ren J et al., 2013; Naber HP et al., 2013; Ferrari-
Amorotti G et al., 2013; Peinado H et al., 2007), strongly indicating that EMT regulates 
invasiveness and tumor aggressiveness. 
It has been demonstrated that EMT has a central role in pancreatic carcinogenesis (Rhim  AD et 
al., 2012). Indeed, in a mouse model of PDAC the dissemination of mesenchymal cells appear to 
occur at a very preliminary stage of the disease (Rhim  AD et al., 2012), indicating that 
mesenchymal cells are able to reach and seed distant organs even before, or in parallel to, 
primary tumor formation. Moreover, the analysis of pathological specimens of PDAC revealed 
that the expression of EMT markers, in particular expression of the transcription factor ZEB1, 
correlates with advanced tumor grade and worse prognosis (Maier HJ et al., 2010).  
EMT has been shown to contribute to drug resistance in several cancer, including PDAC (Shah 
AN et al., 2007). Gene expression profiling of PDAC cell lines demonstrated a strong 
association between the expression of mesenchymal genes and chemotherapy resistance  
(Arumugam T et al; 2009).  In particular, in this study ZEB1 has emerged as upregulated in more 
resistant cell lines, whereas its silencing restored  chemosensitivity and caused re-expression of 
some epithelial markers. All these observation suggest that the expression of mesenchymal 
markers may contribute to drug resistance in pancreatic cancer. 
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CHAPTER II 
 
Genotoxic stress and pancreatic adenocarcinoma  
 
Cancer cells have developed several escape pathways to cope with a wide range of stresses, 
adopting a series of mechanisms that allow cell survival even in the hostile environment. Among 
the various types of stresses, DNA damaging agents, which are able to affect the integrity of the 
genome, are widely studied, since they are commonly used in cancer therapy. Most 
chemotherapeutic drugs directly induce breaks in the genome that injure the DNA chain or 
damage the DNA indirectly, like the topoisomerase inhibitors that target DNA processing 
enzymes. Another class of DNA damaging agents are the antimetabolites, chemical compounds 
which mimic purines or pyrimidines. They are incorporated in the DNA during the S-
phase (synthesis phase) of the cell cycle in which DNA is replicated, interfering with DNA 
production and therefore with normal cell division and growth. Since cancer cells grow faster 
than normal cells, the inhibition of DNA synthesis affects tumor cells more drastically. Although 
most cells are sensitive to DNA damaging agents, some cancer cells often escape to this damage 
thereby surviving to drug treatments. Thus, identification of the molecular mechanisms 
promoting cancer cell survival to genotoxic insults may represent a strategy for improving 
current therapies.  
 
The first-line treatment of locally and advanced PDAC is gemcitabine (dFdC, 2',2'-
difluorodeoxycytidine), a deoxycytidine nucleoside analogue (Burris HA 3rd et al., 1997). Like 
for other nucleoside analogues, the effect of gemcitabine is exerted by its phosphorylated 
metabolites. The transport of gemcitabine into the cell is due to nucleoside transporters, then the 
drug is phosphorylated to the monophosphate (dFdCMP) form by the deoxycytidine kinase 
(dCK). Then, other kinases further phosphorylate dFdCMP to its two active diphosphate and 
triphosphate (dFdCTP) forms (Plunkett W et al., 1995; Mini E et al., 2006). The resulting active 
form dFdCTP, competes with the natural deoxycytidine-triphosphate for incorporation in the 
nascent DNA and RNA chains causing premature termination (Huang P et al., 1991). The 
peculiar features that made gemcitabine the elective agent for the treatment of PDAC are the 
efficient intracellular phosphorylation and its slow rate of elimination (Gesto DS et al., 2012). 
Nevertheless, gemcitabine offers only a marginal benefit in terms of improvement in median 
survival of patients affected by locally advanced or metastatic cancer (Ying JE et al., 2012). 
Hence, PDACs show an initial response to chemotherapy followed by rapid development of drug 
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resistance that allows cancer survival. Although several molecular mechanisms to explain the 
acquired resistance have been proposed (Kim MP and Gallick GE, 2008), the full comprehension 
of the origins of this phenomenon is still lacking.  
 
2.1 Role of RNA binding proteins in genotoxic stress response 
 
In response to DNA damage, cells react by regulating gene expression at many levels. One of the 
most characterized ones is the inhibition of transcriptional activity that is accomplished through 
degradation of the RNA polymerase II (RNAPII) (Kleiman FE et al., 2005). This process allows 
cells to repair the damaged DNA and to overcome the injury. In addition to alteration of 
transcription, recent evidence shows that profound changes in post-trascriptional regulation of 
gene expression occurs in response of genotoxic stress. In particular, high-throughput screening 
of the mammalian transcriptome revealed that a large number of alternative splicing (AS) events 
are differentially regulated after genotoxic treatments (Muñoz MJ et al., 2009; Dutertre M et al., 
2010; Paronetto MP et al., 2011), suggesting that AS may play an important role in cell response 
and survival to DNA damage. AS is one of the major molecular processes involved in the pre-
mRNA maturation. It mediates the elimination of the intronic sequences and the inclusion or the 
exclusion of the exons in the mature mRNA transcript. The resulting differential assortment of 
exons contributes to genome plasticity, creating from a single precursor transcript different 
mRNAs that give rise to multiple protein isoforms with different chemical and biological 
activities (Wang ET et al, 2008). The macromolecular complex that operates the splicing 
reaction is the spliceosome. Its structure is mainly composed of five small nuclear 
ribonucleoprotein particles (snRNPs) and a great number of auxiliary proteins that cooperate 
with the spliceosome to accurately recognize the splice sites and to catalyze the splicing reaction 
(Black DL, 2003). Moreover, several RNA binding proteins (RBPs), also called splicing factors 
(SF), participate in the regulation of AS events, through the binding of specific sequence in the 
transcript. Two main families of SFs are: the serine/arginine-rich (SR) proteins, which generally 
act as positive regulators of exon inclusion (Manley JL and Tacke R, 1996) and the 
heterogeneous nuclear ribonucleoproteins (hnRNPs), which generally mediate exonic silencing 
(Krecic AM and Swanson MS, 1999). 
As mentioned above, AS regulation is part of the cellular response to genotoxic stress. Indeed, it 
has been demonstrated that alterations in AS variants occurs in cancer cells in response to UV 
light, cisplatin or etoposide treatment (Muñoz MJ et al., 2009; Solier S et al., 2004; Paronetto et 
al., 2011). Interestingly, a group of genes that encode for apoptotic proteins are regulated by AS 
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after DNA damage. For instance treatment with inhibitors of topoisomerase I or II favors the 
inclusion of exon 9 in the caspase 2 transcript, thus promoting an anti-apoptotic isoform 
(Solier S et al., 2004). Treatment with DNA damaging agents also affects AS of transcript 
involved in cell motility (i.e. CD44, Filippov V et al., 2007) and proliferation (i.e. Cyclin D1b, 
Muñoz MJ et al., 2009; MDM2 and MDM4, Chandler DS et al., 2006). Changes in AS in 
response to genotoxic stress are accompanied by modulation of SF activity, through the 
modulation of SF cellular localization or the regulation of their post-translational modifications. 
UV treatment causes a relocalization of hnRNPA1 from the nucleus to the cytoplasm, thereby 
probably affecting hnRNPA1 mediated splicing events (Guil S et al., 2006; Biamonti G and 
Caceres JF, 2009). Relocalization in nuclear compartments it is also been observed: after 
genotoxic stress the DDX5 and EWS RNA binding proteins move to nucleoli (Cohen AA et al., 
2008; Paronetto et al., 2011) while a cohort of SFs localize to DNA repair foci where actively 
contributes to the repair of the damage (Gaudreault I et al., 2004; Mirkin N et al., 2008). Co-
localization with foci of active RNAPII has also been observed for the splicing regulator SAM68 
after genotoxic treatment, indicating that residual splicing activity still occurs when cancer cells 
undergo to hostile insults (Busà R et al., 2010).  
 
 
Figure 3: Impact of DNA damage on alternative splicing 
Genotoxic stress cause an alteration of transcription by regulating RNAPII activity and stability, accompanied by 
changes in SF activity. Thus, in this way cancer cell are able to overcome hostile stimuli, surviving to drug 
treatments. (Modified by Dutertre M et al., 2011) 
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Phosphorylation, acetylation and general changes in protein expression of SFs were observed as 
consequences of DNA damage, thereby adding a further level of regulation of AS that might be 
involved in cancer cell escape to injury. Remarkably, significant cellular pathways that are 
activated after stress contributes to the regulation of SFs, like ATM/ATR protein kinases that 
tune the activity of many RBPs (Matsuoka S et al., 2007) and AKT that phoshorylates SRSF1 
thereby regulating its splicing activity (Shultz JC et al., 2010). Collectively, all these 
observations demonstrate that cells respond to DNA damage adapting gene expression through 
changes in the regulation of AS (Fig 3). Thus, cancer cells are able to adapt themselves to hostile 
stimuli that cause genome instability in order to overcome stressful situations and thereby 
survive to genotoxic treatments. Targeting the activity of SFs involved in this escape pathway 
can be an important way to overcome the mechanisms of cell survival and might represent a 
suitable novel approaches to clinical treatments of cancer. 
 
2.2 Role of eIF4E in genotoxic stress response 
 
Stressful situations can lead to changes in translation initiation, a process that is strongly 
regulated since it has important regulatory functions in cell metabolism. The limiting step of the 
regulation of translation is the assembly of the eukaryotic initiation complex (eIF4F) on the 
mRNA 5' cap. This complex is composed by the eukaryotic translation initiation factor 4E 
(eIF4E), which binds to the 5' terminal 7-methyl-GTP (m7GTP) cap of all mRNAs; a scaffold 
protein named eukaryotic translation initiation factor 4 gamma (eIF4G) and the RNA helicase 
named eukaryotic initiation factor 4A (eIF4A), which allows melting of the secondary structure 
of mRNA. Immediately after eIF4F formation, additional factors and ribosomal components are 
recruited thereby allowing the initiation of translation from the nearest start codon (Aitken CE 
and Lorsch JR, 2012). The assembling of the eIF4F complex is strongly regulated. One 
important level of control lies in the availability of eIF4E, the limiting component for the 
initiation complex. The major regulation is due through translation repressor molecules: the 
eIF4E-binding proteins (4E-BPs), which are in turn regulated through phosphorylation by the 
mammalian target of rapamycin (mTOR) kinase (Fingar DC et al., 2002). Phosphorylation of 
4E-BPs causes their release from eIF4E, thus allowing recruitment of eIF4G and formation of 
eIF4F on the cap structure. An additional layer of regulation is represented by the 
phosphorylation of eIF4E on serine 209 by the MAP kinase signal-integrating kinases (MNK1/2) 
proteins. This event occurs in response to activation of the MAPK signal transduction pathways 
(p38 stress MAPK; extracellular regulated kinases ERK1/2) (Buxade M et al., 2008). A number 
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of observations link the eIF4E phosphorylation with cancerogenesis. Animal models 
demonstrated that the inhibition of eIF4E phosphorylation impairs tumor development (Furic L 
et al., 2010; Ueda T et al., 2010). Similar Importantly, in cancer cell several kinds of stresses 
cause eIF4E phosphorylation (Dolniak B et al., 2008), including DNA damaging agents. (Zhang 
Y et al., 2008). Regulation of translation is a key step that allows cells to overcome the insults 
posed by hostile environments. The phosphorylation of eIF4e may contribute to this finely tuned 
regulation, as suggested by the block of cell proliferation and decreased cell survival observed 
after inhibition of MNK activity in prostate, breast and lung cancer (Bianchini A et al., 2008; 
Wheater MJ et al., 2010; Konicek BW et al., 2011). Importantly, the regulation of eIF4E 
phosphorylation can also occur independently from external stimuli. Indeed, alternative splicing 
of the MKNK1 and MKNK2 genes yields four different splice variants: MNK1a/b and MNK2a/b. 
The different protein isoforms differ at their C-terminus: both b-isoforms possess a shorter C-
terminal than the a-isoforms. These splicing events modulate MAPK regulation of MNK 
function,  because the b-isoforms lack the MAPK-interacting domain (Scheper GC et al., 2003; 
O'Loghlen A et al., 2004). The different splicing isoforms also differ for intracellular localization 
and basal activity, MNK1a is prevalently localized in the cytoplasm and show low basal activity 
that is enhanced by different stimuli while MNK1b has high basal activity and is uniformly 
distributed throughout the cell (O'Loghlen A et al., 2007). MNK2a is cytoplasmatic whereas 
MNK2b is partially nuclear and, unlike MNK2a, it does not show high basal activity. Indeed, its 
intrinsic activity is low and is not increased by external cellular stimuli (Scheper GC et al., 
2003). Remarkably, it has been demonstrated that several RNA binding proteins are substrates of 
MNKs, for instance hnRNPA1 (Buxadé M et al., 2005; Guil S et al., 2006) and the 
polypyrimidine-tract binding protein-associated splicing factor (PSF) (Buxadé M et al., 2007), 
underlying the importance of RNA metabolism in the response of cancer cells to various stresses. 
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CHAPTER III 
 
Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of 
the MNK2/eIF4E pathway 
 
Cancer cells are prone to develop escape pathways in order to survive to drug treatments. The 
study presented in this chapter aimed at investigating the involvement of mitogenic activating 
protein kinase interacting kinase (MNK/eIF4E pathway) in the acquisition of gemcitabine 
resistance of PDAC cells.  
The screening of cohort of PDAC patients pointed out a correlation between the phosphorylation 
of eIF4E and disease grade, early onset and worse prognosis. Thus, we investigated the 
involvement of MNK/eIF4E pathway in the pro-survival response of PDAC cells. Interestingly, 
chemotherapeutic drug treatments promoted MNK-dependent phosphorylation of eIF4E and 
MNK inhibition enhanced cell death induced by gemcitabine treatment. Our study revealed that 
MNK2 is primary responsible for the phosphorylation of eIF4E and the survival of PDAC cells 
under genotoxic stress. MNK2 transcript is regulated by alternative splicing producing two 
isoforms: MNK2a and MNK2b. Importanly, the analysis of the expression of these splice 
variants revealed that gemcitabine treatment promotes splicing of MNK2b through the 
upregulation of the SRSF1 proto-oncogene. Importantly, MNK2b overrides the control of 
upstream pathways and its overexpression caused increased resistance to drug treatment. 
Depletion of SRSF1 impaired the effect of this pro-survival pathway. Thus, the results obtained 
in our study identify a novel escape strategy triggered by genotoxic stress in PDAC cells, which 
causes upregulation of the splicing factor SRSF1 and splicing of the MNK2b variant, thus 
allowing phosphorylation of eIF4E independently of external cues.  
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Gemcitabine triggers a pro-survival response in pancreatic cancer
cells through activation of the MNK2/eIF4E pathway
L Adesso1,2, S Calabretta1,2, F Barbagallo1,3, G Capurso2, E Pilozzi2, R Geremia1, G Delle Fave1,2 and C Sette1,3
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive neoplastic disease. Gemcitabine, the currently used chemotherapeutic
drug for PDAC, elicits only minor beneﬁts, because of the development of escape pathways leading to chemoresistance. Herein, we
aimed at investigating the involvement of the mitogen activating protein kinase interacting kinase (MNK)/eIF4E pathway in the
acquired drug resistance of PDAC cells. Screening of a cohort of PDAC patients by immunohistochemistry showed that eIF4E
phosphorylation correlated with disease grade, early onset of disease and worse prognosis. In PDAC cell lines, chemotherapeutic
drugs induced MNK-dependent phosphorylation of eIF4E. Importantly, pharmacological inhibition of MNK activity synergistically
enhanced the cytostatic effect of gemcitabine, by promoting apoptosis. RNA interference (RNAi) experiments indicated that MNK2
is mainly responsible for eIF4E phosphorylation and gemcitabine resistance in PDAC cells. Furthermore, we found that gemcitabine
induced the expression of the oncogenic splicing factor SRSF1 and splicing of MNK2b, a splice variant that overrides upstream
regulatory pathways and confers increased resistance to the drug. Silencing of SRSF1 by RNAi abolished this splicing event and
recapitulated the effects of MNK pharmacological or genetic inhibition on eIF4E phosphorylation and apoptosis in gemcitabine-
treated cells. Our results highlight a novel pro-survival pathway triggered by gemcitabine in PDAC cells, which leads to MNK2-
dependent phosphorylation of eIF4E, suggesting that the MNK/eIF4E pathway represents an escape route utilized by PDAC cells
to withstand chemotherapeutic treatments.
Oncogene advance online publication, 16 July 2012; doi:10.1038/onc.2012.306
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant
neoplastic disease.1 Gemcitabine, the elective agent used in PDAC
chemotherapy, exerts only marginal survival beneﬁts,1 urging
for the identiﬁcation of new agents and/or therapeutic targets. In
this regard, as the PI3K/AKT/mTOR (mammalian target of
rapamycin) pathway is activated in approximately half of PDACs,
correlating with poor prognosis,2 mTOR inhibitors are being
considered as possible therapeutic agents in combination with
chemotherapy. Nevertheless, their efﬁcacy is often limited by
activation of escape pathways leading to phosphorylation of AKT
and eIF4E in response to mTOR inhibition.3,4 For these reasons,
characterization of the molecular mechanisms involved in the
acquisition of drug resistance represents a clinical priority.
The mTOR serine/threonine kinase is a central regulator of protein
synthesis and cell growth.5 mTOR modulates the activity of eIF4E, the
core component of the translation initiation complex eIF4F that
assembles at the 50 cap of eukaryotic mRNAs.5 In quiescent cells,
eIF4E activity is restricted by the 4EBPs (eIF4E-binding proteins).5–7
Nutrients induce phosphorylation of 4EBPs by mTOR, thereby causing
their release from eIF4E and assembly of eIF4F.5 Furthermore, eIF4E
indirectly stimulates translation by favoring nuclear export of selected
mRNAs.6 In line with its central role in cell growth, increased eIF4E
levels can promote neoplastic transformation.7
An additional layer of regulation of eIF4E is provided by its
phosphorylation in serine 209 by the mitogen activated protein
kinase (MAPK) interacting kinases (MNK) MNK1 and MNK2,8,9
which are activated by ERK1/2 and p38.9 Phosphorylation of eIF4E
occurs in cells exposed to growth factors and chemotherapeutic
agents,9,10 and its pharmacological inhibition was shown to
reduce proliferation in cancer cells.11–13 Importantly, although
phosphorylation of eIF4E by MNKs is dispensable for basal protein
synthesis and cell viability,8 it is essential for the transforming
activity of eIF4E in mouse models of cancer,14–16 and it positively
correlates with poor prognosis and disease grade in human
prostate and lung cancers.17,18 These observations point to eIF4E
phosphorylation as a key step in oncogenic transformation.
Noteworthy, as suppression of eIF4E phosphorylation sensitizes
cancer cells to growth arrest11 and stress-induced death19 without
affecting normal development or lifespan in animal models,8 the
MNK/eIF4E pathway appears as a promising pharmacological
target for cancer treatment.
Herein, we have investigated the regulation and function of the
MNK/eIF4E pathway in PDAC. Phosphorylation of eIF4E positively
correlated with grade, and was associated with worse prognosis
and earlier disease onset in PDAC patients. MNK2-dependent
phosphorylation of eIF4E was induced by gemcitabine in PDAC
cells. The drug also promoted upregulation of the splicing factor
SRSF1 and splicing of MNK2b, a splice variant that overrides
upstream regulatory pathways9,20 and confers increased
resistance to gemcitabine. Suppression of this pathway by
pharmacological or genetic inhibition of either MNKs or SRSF1
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synergistically enhanced the cytotoxic effects of gemcitabine. Our
results highlight a novel pro-survival pathway triggered by
gemcitabine in PDAC cells, which leads to MNK2-dependent
phosphorylation of eIF4E, suggesting that the MNK/eIF4E pathway
might represent a promising therapeutic target for PDAC.
RESULTS
Increased phosphorylation of eIF4E in PDAC correlates with worse
prognosis
A cohort of 32 patients diagnosed with primary PDAC in the
absence of metastases, who received surgery with radical intent
(see Supplementary Table 1), was analyzed for the levels of the
phosphorylated form of eIF4E (p-eIF4E) by immunohistochemistry.
We found that 27 samples (84.3%) stained positive for p-eIF4E
(Figure 1a, Supplementary Table 1). A linear score of staining
(range 0–5) was assigned to the samples (Figure 1a; see Materials
and methods), and patients were subdivided in two groups: group
0 comprised eight samples displaying no staining (score 0) or low
p-eIF4E staining (that is, p2), whereas group 1 comprised 24
samples displaying strong p-eIF4E staining (that is, X3)
(Figure 1b). The two groups displayed statistically signiﬁcant
differences only for age at diagnosis, grading, progression-free
survival and overall survival (Figure 1b). Group 1 patients had a
mean age at diagnosis of 64.5, with 95% conﬁdence interval (CI)
59.8–69.2, whereas patients with a low p-eIF4E score (group 0) had
a signiﬁcantly higher mean age at diagnosis of 74.2 (95% CI:
71.9–76.5; P¼ 0.02) (Figure 1b). Notably, of the eight patients
diagnosed at age p60, four had a p-eIF4E score of 5, three had a
score of 4 and one a score of 3 (Supplementary Table 1).
Furthermore, the p-eIF4E score was positively correlated with
tumor grade (G grade, range 1–3; Spearman’s coefﬁcient of rank
correlation (r)¼ 0.6, P¼ 0.0008).
The high p-eIF4E score was also associated with worse survival
probability (log-rank test P¼ 0.02, Figure 1c). Similarly, in a Cox-
proportional hazards regression model, high p-eIF4E score was
associated with worse survival (hazard ratio 4.6; 95% CI: 1–20.1).
Adjuvant therapy (gemcitabine) was associated with a better
overall survival in the Cox-proportional hazards regression model
(hazard ratio 0.3; 95% CI: 0.12–0.85), whereas neither the resection
margins (R status), nor the lymph node status (N stage or lymph
node ratio) were. The mean survival of group 0 patients was 25.1
months (95% CI: 11.3–38.8) as compared with 13 months (95% CI:
8.2–17.8) in group 1 patients (P¼ 0.04) (Figure 1b). Elevated
p-eIF4E was also associated with shorter ‘recurrence-free survival’
(log-rank test P¼ 0.018). Accordingly, the mean time to tumor
recurrence was 20.6 months for group 0 and 9 months for group 1
(P¼ 0.02) (Figure 1b). Collectively, these data suggest that eIF4E
phosphorylation is directly correlated with tumor grade and
associated with worse survival probability.
Therapeutic drugs induce eIF4E phosphorylation in PDAC cells
The marginal survival beneﬁts observed in patients1 may suggest
that chemotherapeutic treatments trigger the activation of pro-
survival pathways in PDAC cells. The MNK/eIF4E and the AKT/
mTOR pathways are two pro-survival routes frequently activated
in cancer.3,4 To test whether they contribute to drug resistance in
PDAC cells, we analyzed activation of key proteins in these
pathways. Phosphorylation of eIF4E was induced by treatment
with gemcitabine in several poorly differentiated PDAC cell lines,
such as MiaPaCa2 (Figure 2a), PT45P1 (Figure 2b) and PANC-1 cells
(Supplementary Figure S1A), as well as in the well-differentiated
HPAF2 cells (Supplementary Figure S1A). Activation of the MNK/
eIF4E pathway was a speciﬁc response, as no increase in AKT
phosphorylation occurred under these conditions (data not
shown), whereas the decreased phosphorylation of the ribosomal
protein rpS6 indicated that the mTOR pathway was inhibited by
gemcitabine (Figures 2a,b).
Next, we tested whether activation of the MNK/eIF4E pathway
was triggered by other chemotherapeutic treatments. eIF4E
phosphorylation was also increased in response to cisplatin in
PDAC cells (Supplementary Figure S1B), whereas neither phos-
phorylation of AKT (data not shown) nor activation of the mTOR
pathway were observed (Supplementary Figure S1B). PDAC cells
were also treated with the mTOR inhibitor rapamycin (1 and
10 nM) for up to 24 h. As for other cancer cells,3,4 mTOR inhibition
caused an increase in phosphorylation of both AKT and eIF4E in
PDAC cells (Supplementary Figures S1C, D). However, AKT
phosphorylation returned to basal levels by 4–24 h of treatment
with the higher dose of rapamycin, whereas eIF4E phosphoryla-
tion persisted for the whole duration of the experiment, regardless
of the dose used (Supplementary Figures S1C, D). These results
suggest that eIF4E phosphorylation is a general, long-lasting
feedback response of PDAC cells to therapeutic treatments.
Inhibition of eIF4E phosphorylation enhances the cytostatic effect
of therapeutic drugs
To test the most effective tool to interfere with eIF4E phosphor-
ylation in PDAC cells, we treated them with inhibitors of kinases
acting upstream of the MAPK/MNK pathway.9 The PI3K inhibitor
(LY294002), MEK1/2 inhibitor (U0126) and p38 inhibitor
(SB202190), alone or in combination, only partially reverted the
increased phosphorylation of eIF4E induced by gemcitabine and
rapamycin in the poorly differentiated MiaPaCa2 and PT45P1 cell
lines (Supplementary Figures S2A, B). However, direct inhibition of
MNKs by their chemical inhibitor MNK-I completely abolished
eIF4E phosphorylation under all treatments (Supplementary
Figure S2A,B). Moreover, MNK-I also strongly reduced gemcita-
bine-induced eIF4E phosphorylation in the well-differentiated
HPAF2 cells (Supplementary Figure S2C). Thus, MNK-I was selected
for further studies.
Dose-response experiments showed that MiaPaCa2 cells were
highly resistant to gemcitabine, with less than 50% growth
inhibition at 100 nM (Supplementary Figure S3A), whereas an
almost complete suppression of PT45P1 cell growth was achieved
at 30 nM (Supplementary Figure S3B). Thus, to test the effect of
MNK-I on PDAC cell growth, we used sub-optimal doses of
gemcitabine (30 nM for MiaPaCa2 and 0.1 nM for PT45P1). MNK-I
alone slightly reduced growth of both cell lines (Figures 2c, d), to
an extent similar to the sub-optimal doses of gemcitabine.
However, the combined treatment with the two drugs synergis-
tically inhibited PDAC cell growth, with an almost complete block
achieved in PT45P1. A similar synergic effect was also observed in
the well-differentiated HPAF2 cells (Supplementary Figure S3C).
Furthermore, inhibition of eIF4E phoshorylation by MNK-I sig-
niﬁcantly augmented the cytostatic effects of cisplatin and
rapamycin (Supplementary Figures S3D, E), indicating that
activation of this pathway exerts a general positive effect in the
stress response of PDAC cells.
Inhibition of MNK activity enhances gemcitabine-induced
apoptosis in MiaPaCa2 cells
Clonogenic assays were performed to directly test whether MNK-I
enhanced the cytotoxic activity of gemcitabine. MiaPaCa2 cells,
which were chosen for their higher resistance to the drug, were
cultured for 24 h with sub-optimal doses of gemcitabine
(0.1–0.3 nM) with or without MNK-I (10 mM) and then grown for
10 days in complete medium (±5 mM MNK-I). Under these
conditions, MNK-I suppressed eIF4E phosphorylation in the large
majority of the cells (Supplementary Figure S4A). Gemcitabine
reduced the number of colonies in a dose-dependent manner,
whereas MNK-I did not signiﬁcantly affect their number
(Figure 3b), even though it reduced the size of colonies
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Figure 1. Phosphorylation of eIF4E in PDAC. (A) Examples of p-eIF4E immunohistochemistry of PDAC tissues. Panels (a–d) show different
intensity of staining. (a) Well-differentiated PDAC with no p-eIF4E staining in the gland and few positive stromal cells (score 0); (b) moderately
differentiated (G2) PDAC tissue with mild cytoplasmic staining in few neoplastic glands (score 1); (c) moderately differentiated (G2) PDAC
tissue showing cytoplasmic staining in most glands (score 2); (d) poorly differentiated (G3) PDAC tissue with strong cytoplasmic staining (score 3).
(B) Summary of the clinical-pathological features associated with patients in group 0 (low p-eIF4E) and group 1 (high p-eIF4E). Categorical
variables were analyzed by Fisher’s test, continuous variables by t-test for independent samples. (C) Survival likelihood of PDAC patients. Group 0
comprised 8 patients with low p-eIF4E staining (scorep2), group 1 comprised 24 patients with high p-eIF4E (scoreX3); P¼ 0.02 at log-rank test.
Patients lost at follow-up are ‘censored’ and marked as small vertical lines.
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(Figure 3a). Notably, the combined treatment with the two drugs
almost completely suppressed colony formation (Figures 3a, b),
conﬁrming a synergic effect.
To understand whether MNK-I affected cell proliferation and/or
death, we analyzed cell cycle progression and apoptosis.
Treatment of MiaPaCa2 cells with MNK-I and gemcitabine for
72 h caused a slight increase in the percentage of cells in G1
(Supplementary Figure S4B). The combined treatment exerted an
additive effect, which was, however, not statistically signiﬁcant. By
contrast, immunoﬂuorescence analysis of the cleaved/activated
form of caspase-3 (Figure 3c, Supplementary Figure S4C) and
TUNEL assays (Figure 3d, Supplementary Figure S4C) documented
that MNK-I signiﬁcantly increased cell death in cells exposed to
gemcitabine, even though it did not trigger apoptosis when it was
administered alone (Figures 3c, d). Notably, MNK-I also enhanced
the cytotoxic effects of cisplatin in MiaPaCa2 cells (Supplementary
Figure S4D). These results suggest that the synergic inhibitory
effect on cell growth and colony formation exerted by MNK-I is
mainly because of enhanced apoptosis in gemcitabine-treated
cells.
MNK2 is required for resistance of MiaPaCa2 cells to gemcitabine
To overcome possible off-target effects of MNK-I, we set out to
interfere with MNK1/2 function by other means. MiaPaCa2 cells
were transfected with MNK1 and MNK2 siRNAs (small interference
RNAs) and depletion of the mRNAs corresponding to both splice
variants was determined by RT–PCR (Figure 4a). Decreased
expression of either MNK1 or MNK2 protein (Figure 4b) reduced
eIF4E phosphorylation under basal conditions, with MNK2
exerting a stronger effect (Figure 4c). Furthermore, the increased
phosphorylation of eIF4E triggered by gemcitabine was comple-
tely suppressed after silencing of MNK2, whereas MNK1 depletion
only slightly reduced it (Figure 4c). Silencing of MNK2 suppressed
gemcitabine-induced eIF4E phosphorylation also in PT45P1 and
HPAF2 cells (Supplementary Figure S5A). These results suggest
that MNK2 is predominantly responsible for eIF4E phosphorylation
in PDAC cells treated with gemcitabine.
Next, MiaPaCa2 cells transfected with si-MNK1 and si-MNK2
were cultured with or without gemcitabine for 48 h. In the
absence of the drug, silencing of either MNK1 or MNK2 caused a
small reduction of cell growth (15–20%) compared with cells
transfected with a control siRNA, whereas concomitant silencing
of both MNKs elicited an additive effect (40% inhibition)
(Figure 4d). However, in the presence of gemcitabine, which
caused a 40% reduction in cell growth per se (Figure 4d), the effect
of MNK2 depletion was signiﬁcantly stronger than MNK1
depletion (75% inhibition vs 60% inhibition). Moreover, depletion
of both kinases did not signiﬁcantly increase the effect of MNK2
depletion alone in cells treated with gemcitabine (Figure 4d).
To investigate whether reduced growth was ascribable to
increased cell death, as in the case of the MNK-I, we analyzed
Figure 2. MNK-dependent phosphorylation of eIF4E supports growth of PDAC cells exposed to gemcitabine. Western blot analysis with
antibodies for the total or phosphorylated forms of the indicated proteins in MiaPaCa2 (a) and PT45P1 (b) cells treated for 8 h with 10 and
30nM gemcitabine. ERK2 was used as loading control. Histograms represent densitometric analysis of p-eIF4E/eIF4E ratio of the gels shown.
Viability of MiaPaCa2 (c) and PT45P1 (d) cell lines was measured by MTS assay after 72 h of exposure to 30 nM gemcitabine alone or in
combination with 10 mM MNK-I. Mean±s.d. of three experiments performed in triplicate; *Po0.01 in paired t-test.
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apoptosis. We found that silencing of neither MNK1 nor MNK2
affected the viability of control cells (Figure 4e). However,
depletion of MNK2, but not MNK1, signiﬁcantly augmented
apoptosis in the presence of gemcitabine (Figure 4e), thus
recapitulating the effect of MNK-I. Importantly, similar results
were also obtained in PT45P1 and HPAF2 cells (Supplementary
Figures S5B, C). These results strongly suggest that MNK2-
dependent phosphorylation of eIF4E contributes to the protective
response of PDAC cells to gemcitabine.
SRSF1 promotes splicing of the MNK2b variant in gemcitabine-
treated MiaPaCa2 cells
On the basis of its prominent role in the response of PDAC cells to
gemcitabine, we focused on MNK2. The MKNK2 gene encodes two
splice variants, named MNK2a and MNK2b.9 Notably, the b variant
lacks the MAPK-interacting domain,20 which uncouples its activation
from this upstream pathway (Figure 5a).9,20,21 Treatment with
gemcitabine for 48 and 72h modulated the expression of MKNK2 in
PDAC cells, by causing a reduction in expression of MNK2 (Figure 5b;
Supplementary Figure S6A). Concomitantly with the reduction,
gemcitabine also altered the ratio between the MNK2 splice variants
in favor of MNK2b (Figure 5b; Supplementary Figure S6A).
Importantly, we found that expression of recombinant GFP-MNK2b
attenuated gemcitabine-dependent cell death in transfected
MiaPaCa2 cells, whereas transfection of GFP-MNK2a did not exert
any effect (Figure 5c; Supplementary Figure S6B). This result
suggests that the shift toward the MNK2b variant in response to
the treatment of MiaPaCa2 cells with gemcitabine contributes to
reduce their sensitivity to the drug.
Figure 3. Inhibition of MNK activity enhances the cytotoxic effect of gemcitabine. (a) Representative images of colonies of clonogenic assays.
(b) Histogram shows colony numbers from three experiments (mean±s.d.). Actual numbers are reported to the left of the histogram.
**Po0.005 in paired t-test. (c, d) Results of the immunofluorescence analyses of the cleaved form of caspase-3 (c) and TUNEL (d) in MiaPaCa2
cells treated as indicated. Histograms represent mean±s.d. of three experiments; *Po0.01 in paired t-test.
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In other cell types splicing of MNK2b is promoted by SRSF1,
a splicing factor of the SR protein family that functions as a proto-
oncogene in vitro and in vivo.21 Remarkably, gemcitabine induced
expression of SRSF1 in MiaPaCa2 and PT45P1 cells (Figure 5d).
SRSF1 upregulation was speciﬁc because other oncogenic splicing
factors, such as hnRNPA122 and Sam68,23 were not affected
(Figure 5d). To investigate the role of SRSF1 in the alternative
splicing of MNK2, we silenced it by RNAi. SRSF1 mRNA was
decreased already at 24 h from transfection (Supplementary
Figure S7), but SRSF1 protein depletion was only observed after
48 h and correlated with increased splicing of the MNK2a variant
(Figure 6a). At this time-point, MiaPaCa2 cells were treated with
gemcitabine for 48 h and analyzed for MNK2b expression and
eIF4E phosphorylation levels. Although SRSF1 silencing did not
affect eIF4E phosphorylation in cells growing in control medium
(Figures 6a, b), it dramatically reduced it in gemcitabine-treated
cells (Figure 6b). Moreover, SRSF1 depletion prevented the
gemcitabine-induced shift of variants ratio toward MNK2b
(Figure 6b), without affecting the reduction in the total levels of
MNK2. These changes in MNK2 splicing and eIF4E phosphorylation
were paralleled by reduced proliferation (Figure 6c) and increased
death (Figure 6d) in SRSF1-depleted cells exposed to gemcitabine,
similarly to what observed by MNK2 silencing and pharmacolo-
gical inhibition of MNK activity.
Collectively, these observations strongly suggest that upon
exposure to gemcitabine, PDAC cells activate a pro-survival
pathway that involves upregulation of SRSF1, splicing of the
MNK2b variant and increased phosphorylation of eIF4E.
DISCUSSION
PDAC is a non curable disease, mainly owing to late diagnosis and
resistance to therapies, which results in rapid progression and
metastatic spreading.1 In this work, we found that various
therapeutic treatments trigger MNK-dependent phosphorylation
of eIF4E in PDAC cell models. The biological relevance of this
phenomenon is indicated by the enhanced cell death in response
to gemcitabine observed in PDAC cells in which eIF4E
phosphorylation is prevented by pharmacological or genetic
approaches. Furthermore, increased phosphorylation of eIF4E
correlates with worse prognosis and disease grade in patients.
Thus, these results suggest that the MNK/eIF4E pathway might
represent a novel potential therapeutic target for PDAC.
Phosphorylation of eIF4E is associated with worse prognosis in
lung cancer,18 and it is required for the oncogenic properties of
eIF4E in animal models.14–16 To investigate whether phos-
phorylation of eIF4E displays clinical relevance in PDAC, we
analyzed a cohort of 32 patients selected for the availability of
detailed clinical and histopathological data and for the absence of
metastases at diagnosis. We found that increased phosphorylation
of eIF4E positively correlated with disease grade and was signi-
ﬁcantly associated with early disease onset in PDAC patients.
Figure 4. MNK2 promotes eIF4E phosphorylation and survival in gemcitabine-treated cells. (a) RT–PCR analysis of the transcripts encoding
MNK1 and MNK2 using primers that distinguish between the a and b variants in MiaPaCa2 cells transfected with the indicated siRNAs.
(b) Western blot and RT–PCR analyses of MNK1 and MNK2 protein and mRNA levels in MiaPaCa2 cells transfected with the indicated siRNAs.
First and second panels show protein amounts of MNK1 or MNK2 after transfection. Actin was used as loading control. PCR amplifications
were obtained with primers common to both splice variants of MNK1 (fourth panel) and MNK2 (fifth panel). (c) Western blot analyses of total
and p-eIF4E levels in MiaPaCa2 cells transfected as in (b) and treated with or without 30 nM gemcitabine (8 h). (d–e) MiaPaCa2 cells transfected
as in (b) were treated with 30 nM gemcitabine (48 h). The histogram in (d) represents cell number of three experiments (mean±s.d.). The
histogram in (e) represents the percentage of cleaved-caspase-3 positive cells of three experiments (mean±s.d.). Statistical analysis was
performed comparing values of cells silenced for MNKs with cells transfected with the scramble siRNA, or between the samples indicated by
brackets; *Po0.05 in paired t-test.
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Furthermore, high eIF4E phosphorylation levels were also asso-
ciated with worse survival and with a shorter mean time to tumor
recurrence. Although the cohort examined in our study was
relatively small, our results were statistically signiﬁcant. However,
as some of the patients were also lost to follow-up relatively early,
more extensive analyses with larger patient numbers will be
required to conﬁrm that eIF4E phosphorylation may represent an
important prognostic marker for PDAC. A larger cohort will also be
necessary to determine whether increased eIF4E phosphorylation
levels reﬂect an underlying biology associated with earlier onset
and more aggressive disease.
Increased phosphorylation of eIF4E occurs in cancer cells of
various organs after exposure to stress stimuli and chemother-
apeutic treatments,9–16 thus suggesting that this pathway allows
cells to survive under adaptive pressures. Our results now indicate
that MNK-dependent phosphorylation of eIF4E also promotes
survival of PDAC cells exposed to therapeutic drugs. Although
pharmacological inhibition of MNK activity had mild effects on cell
growth, it strongly enhanced the cytostatic effect exerted by
genotoxic stress and mTOR inhibition. Our studies indicate that
MNK-I mainly affects cell survival in response to gemcitabine.
Importantly, sub-optimal doses of gemcitabine combined with
MNK-I were sufﬁcient to completely prevent colony formation. As
MNK activity and eIF4E phosphorylation are dispensable for
normal organism development,8 inhibition of this pathway might
be well tolerated in combination with other therapeutic
treatments. In this regard, it also appears promising the recent
observation that inhibition of eIF4E activity by ribavirin exhibited
substantial clinical beneﬁts in acute myeloid leukemia patients
without eliciting toxic responses.24 As chemotherapeutic regimens
exert only marginal effects in PDAC patients,1 our ﬁndings on the
possible role of eIF4E phosphorylation in drug sensitivity of PDAC
cells suggest that targeting eIF4E phosphorylation might
represent a novel strategy to improve therapeutic efﬁcacy.
Notably, this approach might also be useful in combination with
other targeted therapies currently under evaluation in PDAC. For
instance, RAD001 (Everolimus), a small-molecule mTOR inhibitor
derived from rapamycin, exerted positive effects in combination
with gemcitabine in preclinical and clinical studies with metastatic
PDAC patients.25 However, a side effect of blocking mTOR activity
is the increased MNK-dependent phosphorylation of eIF4E.3,4
As inhibition of MNK activity synergistically enhances the
cytostatic effect of mTOR inhibitors in PDAC cells, it is possible
that combined treatment with these molecules might exert
beneﬁcial effects.
Phosphorylation of eIF4E promotes tumor development
in vivo.14–16 The activation of MNKs and eIF4E phosphorylation
reported in several human cancer cell lines further support the
implication of this pathway in oncogenesis.11–13 In line with this
hypothesis, pharmacological inhibition of MNK activity was shown
to reduce protein synthesis,11 cancer cell proliferation11–13 and
development of tumors in vivo.12 However, all these studies did
not document a clear difference between the contribution of
MNK1 and MNK2 to these processes. Our work now suggests that,
although both kinases contribute to eIF4E phosphorylation and
support PDAC cell proliferation under basal conditions, only MNK2
Figure 5. Gemcitabine affects the MKNK2 splice variants ratio in PDAC cells. (a) Schematic representation of the MKNK2 gene showing the
mutually exclusive exons 13a and 13b. (b) RT–PCR analysis of MiaPaCa2 or PT45P1 cells treated with 30 nM gemcitabine. Panels show
expression of splice variants (the arrow indicates a non specific band appearing with increased PCR cycles in PT45P1), total MNK2 levels and
HPRT expression as internal control of the RNA quality. The histograms represent densitometric analysis of the MNK2b/a ratio from three
experiments (mean±s.d.); *Po0.05 in paired t-test. (c) Results of the immunofluorescence analyses of the cleaved form of caspase-3 in
MiaPaCa2 cells overexpressing GFP, GFP-MNK2a or GFP-MNK2b vectors and treated with gemcitabine for 48 h. Bar graphs represent
mean±s.d. of three experiments. Statistical analysis was performed using the paired t-test; *Po0.01. Right panels represent western blots of
the same samples using GFP or MNK2 antibody. (d) Western blot analysis of SRSF1, Sam68 and hnRNPA1 in MiaPaCa2 and PT45P1 cells after
72 h of treatment with the indicated doses of gemcitabine.
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is responsible for the pro-survival effects in cells treated with
gemcitabine. Thus, our results uncover a new MNK2-speciﬁc
function in PDAC cells, which confers resistance to a genotoxic
treatment. As MNK2 was found to be upregulated in hormone-
resistant prostate cancer,12 it will be interesting to test whether it
is more generally involved in the pro-survival responses of cells
that develop resistance to chemotherapeutic treatments.
The MKNK2 gene encodes two mRNA variants, through usage of
alternative last exons named 13a (MNK2a) and 13b (MNK2b).9,20
Gemcitabine caused a reduction in MNK2 expression, mainly
affecting MNK2a levels and thereby altering the splice variant ratio
in favor of MNK2b. We also found that MNK2b partially protected
cells from gemcitabine-induced apoptosis, whereas MNK2a did
not. MNK2b lacks the MAPK-interacting region and it is thereby
uncoupled from upstream MAPK pathways.9,20,21 Thus, it is
possible that its expression in cells treated with gemcitabine
allows higher levels of eIF4E phosphorylation independently from
external cues, which might lead to progressive selection of
chemoresistant cells. Splicing of MNK2b was previously shown
to be regulated by the splicing factor SRSF1 in other cell types.21
We found that gemcitabine induces the expression of SRSF1 in
PDAC cells, which is necessary to favor MNK2b splicing under
genotoxic stress. In the absence of SRSF1, gemcitabine still caused
a reduction in MNK2 levels, but it did not alter the ratio between
the two splice variants, indicating that SRSF1 is required to
promote MNK2b splicing in PDAC cells exposed to the drug.
Moreover, SRSF1 silencing impaired eIF4E phosphorylation and
reduced viability of PDAC cells exposed to gemcitabine. These
observations suggest that SRSF1 upregulation is part of the
pro-survival response triggered by gemcitabine. Interestingly,
SRSF1 is an oncogene frequently upregulated in cancer.21 More
in general, splicing factors are emerging as novel regulators of
oncogenic transformation, and increased expression of some
of them was shown to correlate with malignancy and poor
prognosis.22 Furthermore, mutations that affect splicing of tumor
suppressors, such as BRCA1/2 and APC, resulting in their
inactivation, account for some types of inherited and sporadic
susceptibility to cancer.26,27 Our results now suggest that
increased expression of splicing factors and changes in
alternative splicing of target genes can also occur in response to
chemotherapeutic treatment of cancer cells. Thus, targeting the
activity of splicing factors might represent a novel approach for
combined treatments of speciﬁc cancers. In this regard, it is
noteworthy that the SR protein kinase 1, a key regulator of SRSF1
activity, is also upregulated in PDAC28 and was proposed as a
suitable target for novel therapies.29
In conclusion, our study identiﬁes a novel pro-survival pathway
triggered by gemcitabine in PDAC cells, which relies on MNK2-
dependent phosphorylation of eIF4E, and suggests that targeting
this pathway might represent a promising approach to enhance
the response of PDAC cells to therapeutic agents.
MATERIALS AND METHODS
Tissue, histopathology and clinical information
Immunohistochemistry was performed with a rabbit polyclonal anti
phospho-eIF4E antibody (1:200, Invitrogen, Rockville, MD, USA), as
previously described,18 on parafﬁn-embedded tissue samples from 32
primary non metastatic PDAC patients receiving surgery with radical intent.
All but eight of these patients received gemcitabine-based adjuvant
therapy after surgery. None of the patients received neoadjuvant
treatment. Clinical and histopathological data for each patient were
recorded (Supplementary Table 1). Scoring of p-eIF4E was based on
distribution and intensity of staining in neoplastic cells.18 Distribution was
scored as 0 (0%), 1 (1–50%) and 2 (51–100%). Intensity was scored as 0 (no
signal), 1 (mild), 2 (intermediate), 3 (strong) (Figure 1a). Values were
summed in a total score from 0 to 5. Samples were classiﬁed as ‘low
p-eIF4E’ expression when score was p2 (group 0), and as ‘high p-eIF4E’
expression when score was X3 (group 1). Statistical analysis was
performed by MedCalc 9.6 (www.medcalc.be). Differences for continuous
variables were evaluated by t-test and for categorical variables by Fisher’s
test. Correlation between the expression scores and pathological data was
tested by Spearman’s rank order correlation. Analysis of overall survival
was performed by Kaplan–Meier method and analyzed by log-rank test.
Patients lost at follow-up or whose follow-up ended before the outcome
(death) was reached, are ‘censored’ and marked as small vertical lines in
the survival curves. Univariate and multivariate analyses for risk factors
affecting survival were performed by Cox-proportional hazards regression
model test; a P-value o0.05 was considered as statistically signiﬁcant.
Cell cultures, treatments and extract preparation
MiaPaCa2, PT45P1 and PANC-1 cells were obtained from the Cancer
Research UK Cell Services (Clare Hall Laboratories, Potters Bar, UK); HPAF2
cells were purchased from American Type Culture Collection (ATCC,
Rockville, MD, USA) and generously provided by Professor Aldo Scarpa
(University of Verona). Cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (GIBCO, Carlsbad, CA, USA) (MiaPaCa2) or RPMI 1640
(Lonza, Basel, Switzerland) (PT45P1, PANC-1, HPAF2) supplemented with
10% fetal bovine serum. MNK-Inhibitor (CGP57380), rapamycin, LY294002,
U0126 and SB202190 (EMD Chemical Inc./Calbiochem, Darmstadt,
Figure 6. SRSF1 is required for the modulation of MKNK2 splice
variants by gemcitabine. (a) MiaPaCa2 cells transiently transfected
with scrambled or SRSF1 siRNAs and analyzed after 48 h. Western
blot analysis (first to third panel) of SRSF1, p-eIF4E and tubulin.
RT–PCR analysis (fourth to seventh panel) of SRSF1, MNK2 total
and splice variant mRNA levels (ratio quantified as in Figure 5.
(b) MiaPaCa2 cells were transfected with control or SRSF1 siRNAs
and treated with 30 nM gemcitabine for additional 48 h. Western blot
analysis (first to fourth panel) of SRSF1, eIF4E, p-eIF4E and tubulin.
RT–PCR analysis (fifth to seventh panel) of MNK2 and MNK2 splice
variant mRNA levels as in (a). *Po0.05 in paired t-test. (c, d)
MiaPaCa2 cells were transfected with scramble or SRSF1 siRNAs and
treated with 30 nM gemcitabine for 48 h. The histogram in (c)
represents cell number of three experiments (mean±s.d.). The
histogram in (d) represents the percentage of cleaved-caspase3-
positive cells of three experiments (mean±s.d.). Statistical analysis
was performed comparing values of cells silenced for SRSF1 with
cells transfected with the control siRNA; *Po0.05 in paired t-test.
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Germany) were dissolved in dimethyl sulfoxide and stored at  20 1C.
Gemcitabine (Eli Lilly & Company, Indianapolis, IN, USA) was dissolved in
water. Cisplatin (Sigma-Aldrich, St Louis, MO, USA) was dissolved in RPMI
1640. Stock solutions were diluted to the ﬁnal concentrations in medium.
After incubation, cells were washed with ice-cold phosphate buffered
saline (PBS), resuspended in lysis buffer (100mM NaCl, 15mM MgCl2, 30mM
Tris-HCl pH 7.5, 1mM dithiothreitol, 2mM Na-ortovanadate, 1% Triton X-100
and Protease-Inhibitor Cocktail (Sigma-Aldrich)) and kept on ice for 10min.
Cell extracts were separated by centrifugation at 12 000 r.p.m. for 10min
and diluted in SDS–PAGE sample buffer.
SDS–PAGE and western blot analyses
Western blot analyses of cell extracts (30mg) were performed as previously
described11,30 using the following primary antibody: mouse anti beta
tubulin (1:1000, Sigma-Aldrich); rabbit anti-4EBP1, anti-rpS6 and anti-eIF4E
(1:1000, Cell Signaling Technology, Danvers, MA, USA); rabbit anti-p-rpS6
and anti p-eIF4E (1:1000, Biosource, Carlsbad, CA, USA); mouse anti-SRSF1
and anti-hnRNPA1, rabbit anti-Sam68 and anti-ERK2 (1:1000, SantaCruz
Biotechnology, Santa Cruz, CA, USA). Secondary IgGs conjugated with
horseradish peroxidase (1:10 000; Amersham Bioscience, Piscataway, NJ,
USA) were incubated for 1 h at room temperature and signals were
detected by enhanced chemiluminescence (SantaCruz Biotechnology).
Cell count and viability assays
MiaPaCa2 were seeded at 50 000 cells/plate in 24-well plate and treated as
described in the text for 72 h, washed in PBS, trypsinized and counted
using the Thoma’s chamber. Cell viability was measured by the MTS Cell
Titer 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega,
Madison, WI, USA) according to manufacturer’s instructions by plating
1500 cells (MiaPaCa2) or 3000 cells (PT45P1) per well. Results of cell count
and cell viability assays represent mean±s.d. of three experiments
performed in triplicate.
Colony formation assay
Single-cell suspensions were plated in 100mm plates (3500 cells/plate).
After 1 day, cells were treated for 24 h with gemcitabine (0.1 and 0.3 nM)
and MNK-I (10mM) alone or in combination. At the end of the incubation,
the medium was replaced every 24 h with or without addition of 5 mM
MNK-I. After 10 days, cells were ﬁxed in methanol for 10min, stained
overnight with 10% Giemsa, washed twice in PBS and dried. Pictures were
taken using a digital camera to count the colonies. Results represent the
mean±s.d. of three experiments.
Immunoﬂuorescence analysis
For eIF4E phosphorylation, MiaPaCa2 were seeded at 350 000 cells/plate in
35mm dishes and treated with 30 nM gemcitabine with or without 10 mM
MNK-I for 24 h. Cell lines were then ﬁxed for 10min in 4% paraformalde-
hyde (PFA), permeabilized with 0.1% Triton X-100, processed for
immunoﬂuorescence analysis using the anti p-eIF4E (1:200). For apoptotic
markers, cells were seeded at 250 000 (MiaPaCa2, HPAF2) or 200 000
(PT45P1) cells/plate in 35mm plates and treated with gemcitabine for 72
or 48 h. Immunoﬂuorescence was performed as described above and cell
were stained with anti-cleaved caspase-3 antibody (1:500; Sigma-Aldrich).
For TUNEL assays, ﬁxed cells were permeabilized in PBS containing 0.1%
sodium citrate and 0.1% Triton X-100 and incubated with TUNEL reaction
mixture containing terminal deoxynucleotidyltransferase and ﬂuorescein-
dUTPs at 37 1C for 60min (In Situ Cell Death Detection Kit, Fluorescein,
Roche, Penzberg, Germany). Four random ﬁelds were chosen for each
treatment and at least 100 cells/ﬁeld were counted. Results represent the
mean±s.d. of three experiments.
Cell transfection experiments
pEGFP MNK2a and pEGFP MNK2b vectors were obtained by subcloning
the EcoRI/SalI (MNK2a, 2b) fragments from pEBG (MNK2a) or pCMV5
(MNK2b) (generous gift of Dr CG Proud) in pEGFPC1 vector. MiaPaCa2 cells
were transfected in 35mM plates with 2 mg of plasmid using Lipofectamine
2000 (Invitrogen) by standard methods as described.30,31
MNK1 silencing was obtained using the Smart pool reagent mix from
Dharmacon. MNK2 si-RNA 50-GGAACGUCCUAGAGCUGAU-30 (common to
both splice variants of the gene) and SRSF1 si-RNA 50-CCAAGGACAUU
GAGGACGU-30 were purchased from Sigma-Aldrich. Cells were transfected
at 50% conﬂuence in 35mM plates with 30 nM of siRNAs using
Lipofectamine RNAi MAX reagent (Invitrogen).31
RT–PCR analyses
RNA was extracted using the TRIzol reagent (Invitrogen) and following
manufacturer’s instruction. After digestion with RNase-free DNase (Roche
Diagnostics GmbH), 1 mg of RNA was retro-transcribed (RT) using M-MLV
reverse transcriptase (Invitrogen). PCR primers for MNK1 and MNK2 splice
variants and PCR conditions were previously described.21,32 For MNK1 and
MNK2 expression we used primers that amplify both splice variants: MNK1
forward 50-GAGGTTCCATCTTAGCCCACAT-30 , reverse 50-ACGATGAGCAAT
GCCTTTGGT-30 ; MNK2 forward 50-CGCCTTGGACTTTCTGCATAA-30 , reverse
50-TCACAGATCTTCACGGGGGA-30 . For SRSF1 expression, the following primers
were used: forward 50-ATGTCGGGAGGTGGTGTGATTCGT-30 , reverse 50-TTATGT
ACGAGAGCGAGATCTGCT-30 . Ten percent of the RT reaction was used for each
PCR reaction.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We wish to thank Professor CG Proud for the generous gift of MNK2a and MNK2b
plasmids, Professor A Scarpa for the gift of HPAF2 cells, Dr Enrica Bianchi for help with
FACS analysis, Dr Maria Antonietta Talerico for technical support with immunohis-
tochemistry and Dr Alessia Di Florio for helpful suggestions throughout the study.
This work was supported by funds from the Associazione Italiana Ricerca sul Cancro
(AIRC IG10348) and Association for International Cancer Research (AICR).
REFERENCES
1 Kern SE, Shi C, Hruban RH. The complexity of pancreatic ductal cancers and
multidimensional strategies for therapeutic targeting. J Pathol 2011; 223:
295–306.
2 Falasca M, Selvaggi F, Buus R, Sulpizio S, Edling CE. Targeting phosphoinositide
3-kinase pathways in pancreatic cancer--from molecular signaling to clinical trials.
Anticancer Agents Med Chem 2011; 11: 455–463.
3 Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and
eIF4E survival pathways by rapamycin mediated mammalian target of rapamycin
inhibition. Cancer Res 2005; 65: 7052–7058.
4 Wang X, Yue P, Chan C, Ye K, Ueda T, Watanabe-Fukunaga R et al. Inhibition of
Mammalian Target of Rapamycin Induces Phosphatidylinositol 3-Kinase Depen-
dent and Mnk-Mediated Eukaryotic Translation Initiation Factor 4E Phosphoryla-
tion. Mol Cell Biol 2007; 27: 7405–7413.
5 Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer,
diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21–35.
6 Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E pro-
motes nuclear export of cyclin D1 mRNAs via an element in the 30 UTR. J Cell Biol
2005; 169: 245–256.
7 Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E – from
translation to transformation. Oncogene 2004; 23: 3172–3179.
8 Ueda T, Watanabe-Fukunaga R, Fukuyama H, Fukuyama H, Nagata S, Fukunaga R.
Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of
eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol
2004; 24: 6539–6654.
9 Buxade M, Parra-Palau JL, Proud CG. The Mnks: MAP kinase-interacting kinases
(MAP kinase signal-integrating kinases). Front Biosci 2008; 13: 5359–5373.
10 Zhang Y, Li Y, Yang D. Phosphorylation of eIF-4E positively regulates formation of
the eIF-4F translation initiation complex following DNA damage. Biochem Biophys
Res Commun 2008; 367: 54–59.
11 Bianchini A, Loiarro M, Bielli P, Busa` R, Paronetto MP, Loreni F et al. Phosphor-
ylation of eIF4E supports protein synthesis, cell cycle progression and prolifera-
tion in prostate cancer cells. Carcinogenesis 2008; 29: 2279–2288.
12 Konicek BW, Stephens JR, McNulty AM, Robichaud N, Peery RB, Dumstorf CA et al.
Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initia-
tion factor 4E phosphorylation and suppresses outgrowth of experimental lung
metastases. Cancer Res 2011; 71: 1849–1857.
13 Altman JK, Glaser H, Sassano A, Joshi S, Ueda T, Watanabe-Fukunaga R et al.
Negative Regulatory Effects of Mnk Kinases in the Generation of Chemotherapy-
Induced Antileukemic Responses. Mol Pharmacol 2010; 78: 778–784.
14 Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T et al. Dissecting eIF4E
action in tumorigenesis. Genes Dev 2007; 21: 3232–3237.
eIF4E phosphorylation and drug resistance in PDAC
L Adesso et al
9
& 2012 Macmillan Publishers Limited Oncogene (2012), 1 – 10
15 Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A et al. eIF4E
phopshorylation promotes tumorigenesis and is associated with prostate cancer
progression. Proc Natl Acad Sci USA 2010; 107: 14134–14139.
16 Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R et al. Combined deﬁ-
ciency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor
development. Proc Natl Acad Sci USA 2010; 107: 13984–13990.
17 Graff JR, Konicek BW, Lynch RL, Dumstorf CA, Dowless MS, McNulty AM et al.
eIF4E activation is commonly elevated in advanced human prostate cancers
and signiﬁcantly related to reduced patient survival. Cancer Res 2009; 69:
3866–3873.
18 Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, Hewitt SM et al. Over-
expression of phopsho-eIF4E is associated with survival through AKT pathway in
non-small-cell lung cancer. Clin Cancer Res 2010; 16: 240–248.
19 Chrestensen CA, Eschenroeder A, Ross WG, Ueda T, Watanabe-Fukunaga R,
Fukunaga R et al. Loss of MNK function sensitizes ﬁbroblasts to serum-withdrawal
induced apoptosis. Genes Cells 2007; 12: 1133–1140.
20 Scheper GC, Parra JL, Wilson M, Van Kollenburg B, Vertegaal AC, Han ZG et al. The
N and C termini of the splice variants of the human mitogen-activated protein
kinase-interacting kinase Mnk2 determine activity and localization. Mol Cell Biol
2003; 23: 5692–5705.
21 Karni R, De Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding
the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14:
185–193.
22 David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by
c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 2010; 463:
364–368.
23 Bielli P, Busa` R, Paronetto MP, Sette C. The RNA-binding protein Sam68 is a
multifunctional player in human cancer. Endocr Relat Cancer 2011; 18: 91–102.
24 Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A et al. Molecular
targeting of the oncogene eIF4E in AML: a proof-of principle clinical trial with
ribavirin. Blood 2009; 114: 257–260.
25 Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA et al.
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory meta-
static pancreatic cancer. J Clin Oncol 2008; 27: 193–198.
26 Gonc¸alves V, Theisen P, Antunes O, Medeira A, Ramos JS, Jordan P et al.
A missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2
splicing enhancer motif and causes pathogenic skipping of exon 14. Mutat Res
2009; 662: 33–36.
27 Sanz DJ, Acedo A, Infante M, Dura´n M, Pe´rez-Cabornero L, Esteban-Carden˜osa E
et al. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with
aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 2010; 16: 1957–1967.
28 Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is
associated with tumorigenic imbalance in mitogen-activated protein kinase path-
ways in breast, colonic, and pancreatic carcinomas. Cancer Res 2007; 67: 2072–2080.
29 Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery
as a novel treatment strategy for pancreatic carcinoma. Cancer Res 2006; 66:
3819–3827.
30 Busa` R, Paronetto MP, Farini D, Pierantozzi E, Botti F, Angelini DF et al. The RNA-
binding protein Sam68 contributes to proliferation and survival of human pros-
tate cancer cells. Oncogene 2007; 26: 4372–4382.
31 Pedrotti S, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, Stamm S et al. The splicing
regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2
alternative splicing in spinal muscular atrophy. EMBO J 2010; 29: 1235–1247.
32 O’Loghlen A, Gonzalez VM, Pineiro D, Pe´rez-Morgado MI, Salinas M, Martı´n ME.
Identiﬁcation and molecular characterization of Mnk1b, a splice variant of human
MAP kinase-interacting kinase Mnk1. Experimental Cell Res 2004; 299: 343–355.
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
eIF4E phosphorylation and drug resistance in PDAC
L Adesso et al
10
Oncogene (2012), 1 – 10 & 2012 Macmillan Publishers Limited
20 
 
 
CHAPTER IV 
 
 
The RNA-binding protein Sam68  
 
Sam68 (Src associated during mitosis) is an RNA binding protein of the STAR (Signal 
Transduction and Activation of RNA metabolism) family that links regulation of specific 
mRNAs with signal transduction pathways.  The classic structure of the STAR proteins includes 
an RNA-binding domain, called GSG (GRP33/Sam68/GLD-1), containing a KH domain 
(hnRNP K homology) responsible for the RNA binding, flanked by an N-terminal (NK) and a C-
terminal (CK) regions that allow dimerization of the protein and RNA binding specificity 
(Lukong and Richard, 2003; Vernet and Artzt 1997). In addition to the aforementioned domain, 
Sam68 contains six proline-rich sequences (P0-P5) extending from both sides of the GSG 
domain, which are responsible for the interaction with proteins containing Src homology 3 (SH3) 
and WW domains. The C-terminus of the protein is characterized by a region rich in tyrosine 
residues that are subject to phosphorylation, a modification that affects Sam68 ability to bind 
RNA (Lukong and Richard, 2003) (Fig 4).  
 
Figure 4: The structural and functional domains of Sam68 
In the figure are indicated the GSG domain, containing the KH domain flanked by NK and CK sequences, the 
proline-rich sequences (P0-P5); arginine and glycine rich sequences (“RGG boxes”); tyrosine-rich domain (YY) and 
a nuclear localization signal (NLS). The relative aminoacids positions are indicated (Lukong and Richard, 2003). 
 
 
The nuclear localization signal (NLS) of Sam68 targets this protein prevalently to the nucleus. 
Sam68 controls RNA metabolism at many levels that span from regulation of transcription 
(Hong W et al., 2002; Taylor SJ et al., 2004; Rajan P et al., 2008), to the modulation of splicing 
events (Chawla G et al., 2009; Paronetto MP et al., 2007, 2010; Matter N et al., 2002), to the 
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nuclear export of RNAs  (Li J et al., 2002), and their translation (Grange J et al., 2009; Ben Fredj 
Net al., 2004; Paronetto MP et al., 2006, 2009). The activity of Sam68 is regulated by a large 
number of post-translational modifications that occur in response to various conditions and, in 
most cases, have an impact on its function by regulating its intracellular localization and its 
accessibility to RNA. (Lukong and Richard, 2003; Sette, 2010). 
 
4.1 Sam68 and tumorigenesis 
 
Sam68 was initially proposed as a tumor suppressor because its depletion was reported to cause  
neoplastic transformation of murine NIH3T3 fibroblasts (Liu K et al., 2000). Moreover, 
additional data established that overexpression of Sam68 promotes cell cycle arrest and 
apoptosis (Taylor SJ et al., 2004). However, subsequent studies clearly demonstrated that Sam68 
plays positive roles in cancer cells and it is often overexpressed in human cancers (Busà R and 
Sette C, 2010; Bielli P et al., 2011). For instance, in breast cancer high levels of Sam68 
correlates with short survival rates (Song L et al., 2010) and the attenuation of its expression 
delayed the onset of cancer in an animal model of mammary tumors (Richard S et al., 2008). 
Sam68 function is also required for proper cell proliferation and survival to drug treatment in 
prostate cancer (Busà et al., 2007, 2010). The key mechanism(s) regulated by Sam68 in cancer 
cells is not yet been identified, however it has been shown that this protein promotes tumorigenic 
features through the modulation of alternative splicing events (CD44, BCL-X, cyclin D1 and 
SRSF1; Matter N et al., 2002, Paronetto MP et al., 2007, 2010, Valacca C et al., 2010) (Fig 5). 
Thus, given the strong implication of aberrant regulation of alternative splciing in cancer (David 
& Manley, 2010), it is conceivable that the splicing activity of Sam68 contributes to neoplastic 
transformation in human cancer cells.  
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Figure 5: Cancer cell pathway regulated by Sam68  
Tumorigenesis: Sam68 contributes to invasiveness by regulating the AS in the 3’ UTR of SRSF1, which promotes 
the production of the oncogenic variant ∆Ron that promotes EMT.  
Proliferation: Sam68 modulates the production of Cyclin D1b isoform promoting androgen-dependent cancer cell 
proliferation.  
Migration: Sam68 favors the inclusion of variable exons of CD44 mRNA, inducing the expression of isoforms that 
correlate with cancer progression and invasiveness 
Apoptosis: Sam68 promotes the formation of the pro-apoptotic isoform Bcl-x(s), however tyrosine phosphorylation 
of Sam68 by Src family kinases, reverts this effect causing the expression of the anti-apoptotic variant, Bclx(L).  
(adapted from Bielli et al, 2011).  
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CHAPTER V 
 
The RNA-binding protein PTB 
 
PTB (polypyrimidine tract-binding protein, also called hnRNP I or PTBP1) is an abundant RNA-
binding protein of the hnRNP (heterogeneous nuclear ribonucleoprotein) family involved in 
many different aspects of RNA metabolism. Structurally, PTB consists of four RRM (RNA 
recognition motif) domains all of which are capable of interacting with RNA, with three 
interdomain linkers and an N-terminal leader sequence containing nuclear localization and 
export signals (Fig 6).  
 
 
 
Figure 6: Structural and functional domains of PTB 
PTB contains four RRMs and a nuclear localization signal (NLS). The amino acid sequences of the two other  
isoforms of PTB, PTB2 and PTB4 are shown. Relative aminoacids positions are indicated (adapted from Auweter 
and Allain, 2008) 
 
PTB regulates numerous post-transcriptional steps of gene expression both in the nucleus and in 
the cytoplasm. PTB regulated processes include modulation of alternative splicing events 
(Mulligan GJ et al., 1992; Perez I et al., 1997), 3’-end processing (Lou H et al., 1999; Castelo-
Branco P et al., 2004), mRNA stability (Wollerton MC et al., 2004), IRES (internal ribosome 
entry site) translation (Mitchell SA et al., 2005) and mRNA localization (Sawicka K et al., 
2008). 
PTB itself is subject to alternative splicing regulation, which gives rise to three isoforms: PTB1 
that is the result of the skipping of exon 9, while the inclusion of exon 9 and usage of two 
competing 3’ splice sites produces PTB2 and PTB4 isoforms that differ for the insertion of 19 or 
26 amino acids respectively, between the second and third RNA recognition motif domains (Fig 
5). These alternative splicing isoforms of PTB can vary in activity (Robinson and Smith, 2006; 
Wollerton MC et al., 2001), even though their specific cellular functions have not been described 
accurately.  
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Additional alternative splicing isoforms regulate PTB expression levels. Exon 11 skipping from 
the mature transcript produces a frameshift in the open reading frame, thus causing degradation 
of the mRNA by NMD (Wollerton MC et al., 2004). Notably, PTB autoregulates its own 
expression by modulating exon 11 skipping. 
 
5.1 PTB and tumorigenesis 
 
The role of PTB in cancer is still largely not understood. It has been shown that overexpression 
of PTB acts as inhibitor of cell growth in non small cell lung cancer cells (NSCLC) through the 
induction of the expression of p19Ink4d, an inhibitor of cyclin-dependent kinase 4 (Lin S et al., 
2013). Nevertheless, unlike other tumor suppressor genes, PTB is often increased in cancer cells 
and it has been shown that PTB depletion can reduce the growth of several types of cancer cells 
(Wang C et al., 2008). Depletion of PTB may also affect the invasive behavior of cancer cells 
causing either an inhibition or an increase of invasion in a cell type dependent manner (Wang C 
et al., 2008). 
PTB was found overexpressed in ovarian cancer specimens versus normal controls and its 
depletion was shown to impair tumor cell proliferation, anchorage-independent growth and in 
vitro invasiveness of ovarian cancer cells (He X et al., 2007) strongly indicating a positive role 
for PTB in ovarian cancer. A similar role for PTB has also emerged in brain cancer, as PTB was 
found to be overexpressed in astrocytoma samples and glioblastoma multiforme samples versus 
normal brain tissues (David CJ et al., 2010). Moreover, it has been demonstrated that in this 
system PTB, in concert with hnRNPA1 and hnRNPA2, regulates the alternative splicing of the 
pyruvate kinase mRNA (PKM) promoting the induction of the embryonic pyruvate kinase 
isoform, PKM2, which promotes aerobic glycolysis whereas the adult isoform, PKM1, promotes 
oxidative phosphorylation (Fig 7). The glucose metabolism by aerobic glycolysis is an advantage 
for cancer cells since, despite it produces less energy, this metabolic route can facilitate the 
incorporation of more glycolytic metabolites into the biomass needed for rapid proliferation 
(Chen M et al., 2010). Similar results were also obtained in a cohort of different tumor cell lines 
(Clover CV et al., 2010), suggesting a more general PTB-mediated regulation of PKM splicing 
in cancer cells. All together, these observations strongly suggest that PTB acts as a positive 
regulator for tumorigenesis, at least in part by promoting alternative splicing events that are 
required for tumor cell proliferation. 
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Figure 7: Pyruvate kinase alternative splicing isoforms 
Alternative splicing generates two isoforms from the PKM mRNA: PKM1, resulting from the choice of two 
mutually exclusive exons: 9 (PKM2) and 10 (PKM1). The different isoforms possess different features: PKM1 in 
mainly expressed in adult cells and promote oxidative phosphorylation while PKM2 is express in embryonic cells 
and in cancer cells. This isoform switches the glucose metabolism to aerobic glicolyisis, favoring the proliferation of 
tumor cells. (Modified from David CJ et al., 2010) 
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CHAPTER VI 
 
RNA-binding proteins PTB and Sam68 contribute to the acquisition of the gemcitabine 
resistance in pancreatic cancer 
 
 
The limited effect of conventional chemotherapy in pancreatic adenocarcinoma (PDAC) urges 
for novel therapies, targeting more directly the molecular aberrations of this disease. The 
molecular characterization of the drug resistant phenotype of PDAC cells remain unexplored, 
even though some evidence suggests a correlation with the expression of mesenchymal markers.  
We found that the chronic exposure of PDAC cells to gemcitabine selected a subpopulation of 
cells that are more resistant to drug-induced cell death. This drug resistant subpopulation 
displays a more marked mesenchymal phenotype. Since we previously observed that 
gemcitabine treatment triggers a pro-survival mechanism that relies on upregulation of the 
oncogenic splicing factor SRSF1, we analyzed the expression of a cohort cancer related splicing 
factors in the drug resistant subpopulation. We found that PTB and Sam68 were markedly 
upregulated in drug resistant cells and, importantly, knockdown of PTB and Sam68 partially 
reverted the drug-resistant phenotype, with a more incisive effect for the PTB depletion.  
Thus, our findings strongly indicate that the mechanism responsible for gemcitabine resistance in 
pancreatic cancer involves the upregulation of PTB and Sam68 and their consequent regulation 
of gene expression. Hence, PTB and Sam68 may represent novel suitable molecular targets for 
overcome drug resistance of PDAC. 
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INTRODUCTION 
 
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and malignant 
neoplastic diseases with a 5-years survival rate of  less than 5% (Siegel R et al., 2012; Kem SE et 
al., 2011). Indeed, despite the clinical use of  the chemotherapeutic drug gemcitabine alone or in 
combination, PDAC remains extremely lethal in large part due to poor response to treatments 
(Hidalgo M, 2010). Thus, there is a strong need of further studies aiming at identifying novel 
molecular targets for the development of an innovative strategy to cure this disease. One 
promising strategy could be the identification of the escape pathways that cancer cells can use to 
survive to the genotoxic stress given by the drug treatment. In this regard, we have recently 
shown that PDAC cells are able to trigger a pro-survival mechanism in response to short-term 
treatment with gemcitabine (Adesso L et al., 2013). This escape pathway involves the 
upregulation of the SRSF1 splicing factor (SF), which consequently promotes the splicing of 
MNK2b, a constitutively active isoform of MNK2, thereby establishing a loop that stimulates 
phosphorylation of eIF4E during genotoxic stress and enhances PDAC cell survival.  
Remarkably, growing evidences suggest that the expression of splicing factors is often altered in 
cancer (Grosso AR et al., 2008). This alteration may be responsible for the differential balance 
of the alternative mRNA isoforms in neoplastic cells and tissues with respect to the non 
pathological conditions (Kim E et al.,2008). Emerging evidences report that aberrant expression 
of SFs (Zhou R et al., 2010) and SF regulators (Hayes GM et al., 2006) also occurs in pancreatic 
cancer and the presence of differential splice isoforms has also emerged (Choudhury A et al., 
2000; Hartel M et al., 2008; Wei D et al., 2010; Carrière C et al., 2011; Arafat H et al., 2011). 
Hence, all these observations suggest a central role for the alternative splicing regulation in the 
tumorigenesis of PDAC. SFs may play multiple roles in neoplastic cells. They may act as real 
proto-oncogenes, as SRSF1 that is over-expressed in many human carcinomas and its 
overexpression is sufficient to induce malignant transformation through the regulation of a 
cohort of alternative splicing events (Karni R et al., 2007). Sam68 (Src associated in mitosis) is 
another example of a splicing factor found to be involved in tumorigenesis in various human 
cancers (Bielli P et al., 2011), including prostate cancer where it was shown to contribute to 
proliferation and survival to genotoxic stress (Busà R et al., 2007; 2010). Among the RNA-
binding proteins frequently up-regulated in cancer, there is also PTB (PTBP1, polypyrimidine-
tract-binding protein), which is overexpressed in ovarian (He X et al., 2007) and brain cancers 
(David CJ et al., 2010). PTB depletion affects ovarian cancer cell proliferation and influence 
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brain cancer cell metabolism thought the promotion of the alternative splicing isoform PKM2 
(embryonic variant 2) of the pyruvate-kinase (PK-M gene) mRNA. PKM2 promotes aerobic 
glycolisis instead the adult isoform, PKM1, promotes oxidative phosphorylation. Importantly, it 
has been recently shown that the depletion of PKM2 expression in glioblastoma cells caused an 
increase in cell death thereby suggesting an additional pro-survival role for this alternative 
splicing isoform in cancer (Wang Z et al., 2012). 
Another fundamental cancer related pathway regulated by alternative splicing is the epithelial to 
mesenchymal transition (EMT) (Warzecha CC and Carstens RP, 2012), a process that supports 
cancer cell invasion of tissues and metastatic dissemination (Kalluri R et al; 2003). In particular, 
it has been demonstrated that in PDAC EMT is involved in cancer progression (Rhim AD et al., 
2012) and drug resistance (Arumugam T et al., 2009). All these observations point to a positive 
role exerted by splicing factors in pancreatic cancer.  
In the present work, we investigated the involvement of splicing factors to the long-term 
selection of a drug-resistant (DR) subpopulation of cancer cells. We observed that chronic 
gemcitabine treatment of PDAC cells caused the formation of DR subpopulations highly 
resistant to genotoxic stress. DR subpopulations displayed mesenchymal features with respect to 
the parental cells (PCL), a change that is accompanied by an increased expression of 
mesenchymal makers and enhanced cell migration. Importantly, we found that Sam68 and PTB 
were up-regulated in the DR-subpopulation and that their expression is required to promote 
survival of DR-cells to genotoxic stress. Hence, our results indicate a positive role for Sam68 
and PTB in the acquisition of drug resistance and suggest that these splicing factors may 
represent novel promising potential therapeutic targets for PDAC. 
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RESULTS 
 
Characterization of drug-resistant (DR)-PDAC cells  
 
To isolate a drug-resistant sup-populations, we chronically treated Pt45P1 cell line, which 
displays higher sensitivity to the drug, and the more resistant PANC-1 cell line, with 
gemcitabine. Chronic treatment with gemcitabine caused massive cell death in both cell lines. 
However, 15 days after removal of the drug, few viable clones were visible in the plates of both 
cell lines. Selected clones were pooled and amplified (Figure 1A). Every week, a 24 hour-pulse 
of gemcitabine was performed to maintain drug selection of the DR populations. To evaluate if 
DR-cells were indeed more resistant to drug treatment than the original parental cell lines (PCL), 
a dosage of gemcitabine was performed. After 72 hours of gemcitabine treatment, cell death was 
evaluated by trypan blue cell count and immunofluorescence analysis of the cleaved/activated 
form of caspase-3. Drug treatment caused a much more dramatic induction of cell death in PCL 
cells than in DR-PDAC cells (Figure 1B and 1C), confirming that the selected DR-cells were 
more resistant to the gemcitabine-induced cell death than the corresponding parental cell lines 
from which they have originated. Clonogenic assay was perform to further confirm the acquired 
drug resistance of the DR-PDAC populations. PCL and DR cells were cultured for 24 hours with 
sub-optimal doses of gemcitabine and then allowed to growth in complete medium in order to 
form visible colonies in the plates. Treatment with gemcitabine reduced the number of colonies 
in a dose dependent-manner in PCL cells. However, DR cells were resistant to the lowest dose of 
drug used and the reduction in colony number was less pronounced even at higher doses (Figure 
2A, 2B and C). Moreover, we measured the diameter of the colonies as an additional indicator of 
cell survival after treatment. Gemcitabine treatment affected the size of the colony in a more 
incisive manner in PCL than in DR cells even at the lower dosage, again highlighting the 
enhanced resistance to gemcitabine of the DR cells (Figure 2D). Collectively, all these results 
indicate that the DR-PDAC cell populations have acquired a drug-resistant phenotype. 
 
 
DR-PDAC cells express mesenchymal markers 
 
Previous observations correlated the acquisition of chemoresistance to gemcitabine with with an 
epithelial-to-mesenchymal transition (EMT) of PDAC cells (Shah AN et al., 2007; Wang Z et 
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al., 2009; Arumugam T et al., 2009). Thus, we performed an immunofluorescence with 
phalloidin in order whether DR-PDAC cells acquired differences a mesenchymal-like actin 
cytoskeleton morphology. We found that DR cells acquired a spindle shape while PCL cells 
appeared more cobblestone-like, suggesting that DR cells could possess mesenchymal features 
(Figure 3A). Next, we analyzed the expression of epithelial and mesenchymal markers and we 
found that DR cells overexpress markers of the mesenchymal phenotype like the transcription 
factors ZEB1, TWIST and SLUG, whereas the epithelial markers ESRP1/2 were repressed 
(Figure 3B). SNAIL and ZEB2 trascriptional factors were downregulated or unchanged in both 
DR-PDAC populations. This result could be explained by the observation that up-regulation of 
SNAIL and ZEB2 occurs in a preliminary stage of the EMT, while ZEB1, TWIST and SLUG are 
required for the maintenance of the stable mesenchymal phenotype (Thiery JP et al., 2009). 
 
DR-PDAC cells displays enhanced migratory ability 
 
EMT is associated with an enhancement of cancer cell ability to migrate and metastasize distal 
organs (Kalluri R et al; 2003). Thus, we investigated if the DR-populations showed increased 
cell migration. We performed a wound-healing assay in which cells are plated at very high 
density to minimize the effect of proliferation and then a scar is performed in the plate. 
Evaluation of the percentage of the closure of the scar after 6h clearly indicated that DR-cells 
were faster than PCL in filling the wound, thereby indicating their enhanced migratory capability 
(Figure 3C). 
 
 
Sam68 and PTB are up-regulated in DR-PDAC cells 
 
Up-regulation of the splicing factor SRSF1 was previously observed after short-term 
gemcitabine treatment in PDAC cells (Adesso L et al., 2013). Thus, we asked whether DR-cells 
may differ from PCL cells in the expression of specific splicing factors. Western blot analyses 
were performed to investigate whether a cohort of cancer-related splicing factors were 
differentially expressed in the DR populations. We found that Sam68 and PTB were markedly 
up-regulated in both DR-Pt45P1 and DR-PANC-1 cells (Figure 4A and 4B). Up-regulation of 
SRSF1 was detected in DR-Pt45P1 cells but not in DR-PANC-1 cells, possibly because PANC-1 
cells are already more resistant to gemcitabine and express higher basal levels of SRSF1.  
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Downregulation of Sam68 and PTB sensitize DR-PDAC cells to gemcitabine-induced cell 
death  
 
To investigate whether Sam68 and PTB played a role in DR-cell survival, we depleted their 
expression by si-RNA and then analyzed DR-cell survival after treatment with gemcitabine. 
Sam68 and PTB were silenced either alone or in combination, in order to observe if the depletion 
of both protein could exert an additive effect on cell survival (Figure 5A). Downregulation of 
either Sam68 or PTB alone rescued drug-induced cell death in DR cells, as determined by trypan 
blue cell count  (Figure 5B) and immunofluorescence analysis of the cleaved/activated form of 
caspase-3 (Figure 5C). However, no additive effect was observed when both protein are depleted 
together (Figure 5B and 5C), possibly suggesting that the two splicing factors function in the 
same pathway of gene expression regulation. These results indicate that Sam68 and PTB are 
required for the drug-resistant phenotype of DR-PDAC cells. 
 
Pyruvate-kinase (PKM) alternative splicing is modulated in DR-PDAC cells 
 
A key alternative splicing event modulated by PTB is the alternative splicing of the pyruvate-
kinase mRNA. PTB overexpression enhances the formation of the PKM isoform 2 (PKM2), a 
splicing variant express in embryo and re-expressed in cancer cells, responsible for the switch of 
cell metabolism from oxidative phosphorylation to aerobic glycolisis (David CJ et al., 2010; 
Clower CV et al., 2010). Importantly, depletion of PKM2 variant impairs glioblastoma cells 
survival indicating that this isoform could exert a protective role in cancer cells (Wang Z et al., 
2012). To determine whether PKM alternative splicing was differentially regulated in DR-cells, 
we analyzed the expression of PKM1 and PKM2 variant as previously reported (David CJ et al., 
2010) (Figure 6A). RT-PCR analysis showed that DR-cells express mainly PKM2 isoform while 
parental express comparable levels of PKM1 and PKM2 isoforms (Figure 6B). Importantly, 
depletion of PTB expression restored the ratio between PKM1 and PKM2 isoforms in a similar 
manner of the parental cells (Figure 6C). Thus, PTB expression is required for the up-regulation 
of PKM2 in DR-cells. 
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DISCUSSION 
 
 
Since pancreatic cancer still remains an aggressive and non curable pathology (Siegel R et al., 
2012; Kem SE et al., 2011), the characterization of the key modulators of escape pathways 
remains a crucial step for the development of novel therapeutic approaches. In the study 
presented here we found that chronic treatment with gemcitabine induced the selection of a drug 
resistant population of cells in two different PDAC cell lines. Importantly, we found that the 
drug-resistant phenotype relied on the upregulation of two cancer-related splicing factors: PTB 
and Sam68. It has been previously demonstrated that the regulation of alternative splicing 
mediated by splicing factors, is a critical response that cancer cells trigger in order to overcome 
hostile stimuli, including stresses caused by chemotherapeutic treatments (Dutertre M et al., 
2011; Busà R and Sette C, 2010). Regulation of post-trascriptional gene expression through 
alternative splicing was found to be an essential step for cancer cell homeostasis, as mutations in 
core components of the spliceosome are a frequent feature of cancer cells and treatment with 
synthetic derivatives that target spliceosomal components result in antitumoral effects (Bonnal S 
et al., 2012). Thus, we investigated whether there were alterations in the expression of a cohort 
of selected splicing factors in DR-PDAC cells, chosen because it was demonstrated that these 
RNA binding proteins are often overexpressed in cancer (Grosso AR et al., 2008). Importantly, 
we found that Sam68 and PTB were markedly up-regulated in DR-PDAC cells with respect to 
the parental cells from which they have originated. A positive role for Sam68 in cancer has 
already been extensively described. Sam68 is highly express in cancer and its depletion affects 
prostate and breast cancer cell proliferation (Busà R et al., 2007; Song L et al., 2010). Moreover, 
higher levels of Sam68 correlate with shorter survival rates of breast cancer patients (Song L et 
al., 2010) while haploinsufficiency of Sam68 can delay the onset of mammary tumors and can 
decrease metastasis in an animal model of breast cancer (Richard S et al., 2008). Thus, higher 
expression of Sam68 in cancer seems to be responsible for a more aggressive tumor behavior. 
Several studies also demonstrated that PTB is up-regulated in cancer, particularly in ovarian 
cancer where PTB depletion affects cancer cell proliferation and invasiveness (He X et al., 
2007). Thus, to investigate if Sam68 and PTB exert a protective role in DR-PDAC cells, we 
depleted their expression and we evaluated DR-PDAC cell survival after gemcitabine treatment. 
We found that knockdown of Sam68 or PTB rescues sensitivity to drug treatment of the DR sub-
populations, indicating that their overexpression is required for the acquired resistance to 
gemcitabine. We were not able to observe an additive effect when both proteins are depleted 
simultaneously in DR-PDAC cells. One explanation of this phenomenon could be that Sam68 
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and PTB are both required on the same molecular pathway thus, the depletion of one of them is 
sufficient to impair this function. 
Genotoxic stress modulates the intra-nuclear localization and the function of Sam68 in prostate 
cancer cells and its depletion affects cancer cell survival to drug treatment (Busà R et al., 2007, 
2010), clearly indicating that Sam68 expression promotes the survival to DNA damage. Similar 
studies have not been performed for PTB. However, up-regulation of PTB was also been 
observed in brain tumors and other carcinomas (David CJ et al., 2010; Clower CV et al., 2010). 
In these systems, PTB, together with hnRNP A1 and A2, controls cancer cell metabolism 
through the regulation of the alternative splicing of the pyruvate-kinase mRNA (PKM gene). 
PTB promotes the PKM2 variant which is physiologically expressed in embryo and it has been 
found re-expressed in cancer. PKM2 variant switch the glucose metabolism from oxidative 
phosphorylation to aerobic glycolysis, a change that promotes cancer cell proliferation (Chen M 
et al., 2010). Hence, PTB overexpression seems to favour tumor cell establishment. Recent 
evidence has also demonstrated that the depletion of PTB-induced PKM2 variant in glioblastoma 
cell line caused apoptosis (Wang Z et al., 2012), indicating the involvement of PTB in the 
protection of cell death thought the modulation of PKM splicing. Importantly, we found that in 
DR-PDAC cells the ratio between PKM1 and the PKM2 variant favours the PKM2 variant with 
respect to PCL which express similar levels of PKM1 and PKM2. Strikingly, depletion of PTB 
in DR-PDAC cells re-established the ratio in PKM variants observed in PCL cells, suggesting 
that modulation of this splicing event is part of the mechanism by which PTB promotes drug 
resistance in PDAC cells.  
A key step involved in gemcitabine resistance in PDAC is the epithelial to mesenchymal 
transition (EMT), a process strongly regulated by alternative splicing (Warzecha CC and 
Carstens RP, 2012; Biamonti G et al., 2012). The expression of mesenchymal markers was 
found to be correlated and to be responsible for high resistance to gemcitabine in PDAC 
(Arumugam T et al., 2009). Analysis of cell morphology and EMT markers demonstrated that 
DR-PDAC cells shows a mesenchymal phenotype that results in enhanced cell migration. 
Importantly, both Sam68 and PTB were previously proposed to be involved in the promotion of 
the mesenchymal status. Sam68 regulates the expression of SRSF1 through modulation of an 
alternative splicing event in the SRSF1 3’UTR; higher levels of SRSF1 in turn favour splicing of 
the ∆Ron variant that promotes EMT and enhances cell migration (Valacca C et al., 2010). PTB 
promotes the formation of the mesenchymal-related alternative splicing isoform of the FGFR2 
receptor (Carstens RP et al., 2000), a splicing variant found to be expressed in poorly 
differentiated tumors (Grosso AR et al., 2008). Thus, it could be possible that the overexpression 
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of Sam68 and PTB in DR-PDAC cells is also required to maintain the mesenchymal phenotype 
that characterizes this populations.  
In conclusion, our studies identify that chronic treatment with gemcitabine selects drug resistant 
PDAC cells that are capable to survive more efficiently to drug treatment. This phenotype relies 
on the up-regulation of Sam68 and PTB and their mediated protective role in response to drug 
treatment. Thus, our results suggest that Sam68 and PTB could represent novel molecular targets 
for therapeutic approaches aimed at enhancing the response of PDAC cells to chemotherapeutic 
drugs. 
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MATERIALS AND METHODS 
 
Cell Culture and treatments 
Pt45P1 and PANC-1 parental cells and DR cells were cultured in RPMI 1640 medium (Lonza), 
supplemented with 10% fetal bovine serum (Lonza), penicillin and streptomycin and grown in a 
37°C humidified atmosphere of 5% CO2. Gemcitabine (Eli Lilly & Company, Indianapolis, IN, 
USA) was dissolved in water and stored at -20 °C. 
 
Cell transfections 
For RNA interference, cells at ~50-60% confluence were transfected with siRNAs (Sigma-
Aldrich) using Lipofectamine RNAiMAX (Invitrogen) and OptiMEM medium (Invitrogen), 
according to the manufacturer’s instructions. Sequences and conditions for SAM68 siRNA were 
previously described (Busà R et al., 2007). PTB silencing was obtained using the Smart pool 
reagent mix from Dharmacon, cells at 50/60% confluency were transfected for 2 consecutive 
days with 30 nM of siRNAs. 
 
RT-PCR analysis 
Total RNA was extracted from cells using Trizol reagent (Invitrogen) according to the 
manufacturer’s instructions. After digestion with RNase free DNase (Ambion), RNA was 
resuspended in RNase free water (Sigma Aldrich); 1µg of total RNA was used for RT-PCR using 
M-MLV reverse transcriptase (Promega). Five percent of the RT reaction was used as template 
for PCR analysis (GoTaq, Promega). Primers used to amplify SLUG, SNAIL and ZEB2 were 
described elsewhere (Valacca C et al., 2010; Evdokimova V et al., 2009; Beltran M et al., 2008). 
Primers and conditions used for the analysis of the pyruvate-kinase isoforms were described 
elsewhere (David CJ et al., 2010). The sequences of all additional primers used are listed in 
Table1. 
 
Protein extraction and Western blot analysis 
For protein extraction, cells were resuspended in lysis buffer (150 mM sodium chloride, 1.0% 
NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 50 mM Tris pH 8.0). After 
10 min of incubation in ice, the extracts were centrifuged for 10 min at 12,000 rpm at 4°C and 
the supernatants were collected for further analysis. Western blot analysis was performed as 
previously described (Paronetto MP et al., 2007). Following primary antibodies (overnight at 
4°C) were used: rabbit anti-Sam68 (1:1000, Santa Cruz Biotechnology), goat anti-PTB (1:500, 
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Santa Cruz Biotechnology), mouse anti-SRSF1 (1:1000, Santa Cruz Biotechnology), mouse anti-
hnRNPA1 (1:1000, Sigma-Aldrich) mouse anti-hnRNPA2/B1 (1:1000, Sigma-Aldrich), mouse 
anti-hnRNRP F/H (1:1000, Abcam) Secondary anti-mouse, anti-rabbit or anti-goat IgGs 
conjugated to horseradish peroxidase (Amersham) were incubated for 1 h at RT (1:10000). 
Immunostained bands were detected by chemiluminescence method (Santa Cruz Biotechnology). 
 
Coomassie staining 
After separation on 10% SDS-PAGE, protein bands were visualized by placing gels in a solution 
of 40% distilled water, 10% acetic acid, and 50% methanol with the addition of 0.25% by weight 
Coomassie Brilliant Blue R-250 (Sigma-Aldrich). Gels were incubated 2 hours at room 
temperature and then transferred in a mixture of 40% distilled water, 10% acetic acid, and 50% 
methanol, placed on shaker for washing. The washing mixture was replaced with fresh rinse 
mixture until the excess dye has been removed. 
 
Colony formation assay 
Single-cell suspensions were plated in 35mm plates (500 cells/plate for Pt45P1 PCL and DR; 
750 cells/plate for PANC-1 PCL and DR). After 1 day, cells were treated for 24 h with 
gemcitabine. At the end of the incubation, the medium was replaced every 48 h. After 10 days 
for Pt45P1 and 12 days for PANC-1, cells were fixed in methanol for 10 min, stained overnight 
with 5% Giemsa, washed twice in PBS and dried. Pictures were taken using a digital camera to 
count and measure the colonies. 
 
Trypan blue cell count  
PCL and DR cells were seeded at ~70% confluence in 24-well plate and treated as described in 
the text for 72 h, washed in PBS and trypsinized. Cellular suspension was incubated with of 
0.4% Trypan Blue Stain (Sigma-Aldrich) and cells were counted using the Thoma’s chamber. 
 
Immunofluorescence analysis 
For phalloidin analysis, PCL and DR cells were fixed in 4% paraformaldehyde and washed three 
times with PBS. Cells were permeabilized with 0.1% Triton X-100 for 10 min and incubated for 
1 h in 3% BSA. Cells were washed three times with PBS and incubated for 2 h at room 
temperature with antibodies (anti-phalloidin 1:400, Sigma-Aldrich). For apoptotic markers, 
immunofluorescence was performed as described above and cell were stained with anti-cleaved 
caspase-3 antibody (1:400; Sigma-Aldrich), followed by 1 h of incubation with secondary 
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antibodies,cy3-conjugated donkey anti-rabbit (1:500; Jackson Immunoresearch, Bar Harbor, ME, 
USA). Hoechst dye (0.1mg/ml; Sigma–Aldrich) was added for the last 45 min. Slides were 
mounted in Mowiol 4–88 (Calbiochem, Darmstadt, Germany). Results represent the mean ± S.D 
of three experiments. At least 1000 cells for PCL or DR in each experiment were counted.   
 
Scratch wound-healing motility assay 
PCL and DR cells were plated at 60% of confluence and incubated at 37 °C until the plate was 
confluent. A wound by scratching with a sterile pipette tip was created. The plate was 
photographed immediately and 6h after scratching. 
 
 
Table1- Sequences of primers used for PCR analysis. 
 
TWIST1 Fw 5’-CATGTCCGCGTCCCACTAG-3’ 
TWIST1 Rev 5’-TGTCCATTTTCTCCTTCTCTGG-3’ 
ESRP1 Ex1 Fw 5’-GGCTCGGATGAGAAGGAGTTGAT-3’ 
ESRP1 Ex3 Rev 5’-GAAGGAAGTCCCTACTCCAAT-3’ 
ESRP2 Ex2 Fw 5’-ACGCTGCACAAATCGCTGGTT-3’ 
ESRP2 Ex3 Rev 5’-GTGCAGGACCTGTCGCAAT-3’ 
ZEB1D Fw 5’-CATTGCTGACCAGAACAGTGTTCC-3’ 
ZEB1E Rev 5’-TGGGCGGTGTAGAATCAGAGTCAT-3’ 
HPRT Fw 5’-TGACCAGTCAACAGGGGACA-3’ 
HPRT Rev 5’-TTCGTGGGGTCCTTTTCACC-3’ 
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Figure legends 
 
Figure 1: Chronic gemcitabine treatment selects DR-PDAC cells 
(A) Schematic illustration of the experimental plan adopted to select drug resistant DR-PDAC 
cells. (B) Trypan blue cell count was performed to analyze cell survival after gemcitabine 
treatment. Bar graph represents the mean + SD of 3 experiments, each performed in triplicate, in 
which PCL and DR were compared. *P < 0.05 in paired t-test, **P < 0.01 in paired t-test . (C) 
Analysis of apoptosis in PCL and DR treated as indicated through the staining with anti-cleaved 
caspase 3. Bar graph represents the mean +SD of 3 experiments, each performed in duplicate. *P 
< 0.05 in paired t-test, **P < 0.01 in paired t-test. 
 
 
Figure 2: Clonogenic assay confirm the higher resistance of DR-PDAC cells 
(A) Representative images of colonies of Pt45P1 PCL (upper panels) and DR (lower panels). (B) 
Representative images of colonies of PANC-1 PCL (upper panels) and DR (lower panels). (C) 
Histograms shows % of cell survival calculated as the ratio of % of colony numbers in treated 
plates vs control. Data represents three experiments (mean + S.D.). *P < 0.05 in paired t-test, **P 
< 0.01 in paired t-test. (D) Analysis of colony size, bar graph represents the mean + S.D. of 3 
experiments. *P < 0.05 in paired t-test, **P < 0.01 in paired t-test. 
 
 
Figure 3: DR-population express mesenchymal markers and increased cell migration  
(A) Representative images (40x magnification) of PCL and DR cells stained for phalloidin. 
White bars = 50 µm. (B) RT-PCR analysis of mesenchymal and epithelial markers in PCL and 
DR cells. HPRT was used as loading control. (C) Wound healing assay of PCL and DR cells. 
The % of wound closure was calculated as a % of reduction of the scar length compared with the 
initial scar length. Data represents three experiments (mean + S.D.). **P < 0.01 in paired t-test. 
 
 
Figure 4: Sam68 and PTB are upregulated in DR-PDAC cells 
Western blot analysis of cancer-related splicing factors in Pt45P1 (A) and PANC-1 (B) parental 
PCL and DR. Gels were also stained with Coomassie (right panels) as loading control.  
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Figure 5: Downregulation of Sam68 and PTB sensitizes DR-PDAC cells to gemcitabine-
induced cell death 
(A) Western blot analysis of Sam68 and PTB expression after two cycles of transfection with 
indicated si-RNA in Pt45P1 and PANC-1. Coomassie staining was used as loading control. (B) 
Trypan blue cell count was performed in PCL, DR-DPAC cells scr and DR-PDAC cells depleted 
for Sam68 and/or PTB to analyze cell survival after gemcitabine treatment. Bar graph represents 
the mean + S.D. of 3 experiments, each performed in triplicate. **P < 0.01 in paired t-test. (C) 
Analysis of apoptosis through the staining with anti-cleaved caspase 3 in PCL and DR-DPAC 
cells scr and DR-DPAC cells depleted for Sam68 and/or PTB treated as indicated. Bar graph 
represents the mean + S.D. of 3 experiments, each performed in duplicate. Statistical analysis 
was performed comparing values of PCL cells and DR-PDAC scr cells and comparing DR-
PDAC cells silenced for Sam68 and/or PTB with DR cells transfected with the scramble siRNA. 
**P < 0.01 in paired t-test. 
 
Figure 6: Modulation of PKM alternative splicing isoforms in DR-PDAC cells 
(A) Schematic representation of the PKM alternative splice-variants. Black arrows indicates 
primers used for PCR analysis, which was followed by PstI digestion, in order to distinguish 
between PKM1 and PKM2 products. (B) RT–PCR analysis of PKM isoforms. Panels show 
expression of the PKM1 and PKM2 isoforms in PCL and DR-PDAC cells. (C) RT–PCR analysis 
of PKM isoforms after PTB depletion. Panels show expression of the PKM1 and PKM2 isoforms 
in PCL and DR-PDAC cells depleted or not for PTB expression. 
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 APPENDIX 
 
 
The RNA binding protein SAM68 transiently localizes in the chromatoid body of male germ 
cells and influences expression of select microRNAs 
 
 
SAM68 is important for proper mouse spermatogenesis and male fertility, a regulation exerted 
by its role in the nodulation of alternative splicing and transaltion of specific mRNAs. We 
identify an additional level of SAM68-mediated regulation in male germ cells. In the present 
study we observe a transient localization of SAM68 in the chromatoid body (CB) during the 
meiotic divisions of mouse spermatocytes. The chromatoid body (CB) is a specific male germ 
cells structure in which a cohort of proteins that regulates RNA metabolism were identified. 
Importantly, several regulators of microRNA biogenesis were also identified in the CB. The 
presence of SAM68 in the CB is not required for its assembling, neither for the localization of 
MVH in the CB, one of its major components. However, SAM68 ablation impairs the maturation 
of a cohort of microRNA. We also demonstrate that SAM68 interacts with DROSHA and 
DICER in secondary spermatocytes and early round spermatids. These results suggest a novel 
role for SAM68 in the regulation of miRNA pathway during spermatogenesis. 
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Abstract
The chromatoid body (CB) is a unique structure of male germ cells composed of thin filaments that condense into
a perinuclear organelle after meiosis. Due to the presence of proteins involved in different steps of RNA metabolism and of
different classes of RNAs, including microRNAs (miRNAs), the CB has been recently suggested to function as an RNA
processing centre. Herein, we show that the RNA binding protein SAM68 transiently localizes in the CB, in concomitance
with the meiotic divisions of mouse spermatocytes. Precise staging of the seminiferous tubules and co-localization studies
with MVH and MILI, two well recognized CB markers, documented that SAM68 transiently associates with the CB in
secondary spermatocytes and early round spermatids. Furthermore, although SAM68 co-immunoprecipitated with MVH in
secondary spermatocytes, its ablation did not affect the proper localization of MVH in the CB. On the other hand, ablation of
the CB constitutive component MIWI did not impair association of SAM68 with the CB. Isolation of CBs from Sam68 wild
type and knockout mouse testes and comparison of their protein content by mass spectrometry indicated that Sam68
ablation did not cause overall alterations in the CB proteome. Lastly, we found that SAM68 interacts with DROSHA and
DICER in secondary spermatocytes and early round spermatids and that a subset of miRNAs were altered in Sam682/2germ
cells. These results suggest a novel role for SAM68 in the miRNA pathway during spermatogenesis.
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Introduction
Spermatogenesis is characterized by a complex regulation of
gene expression. Male germ cells have to face an extended period
of silencing of the genome, which occurs during meiotic
homologous recombination and during morphological differenti-
ation of haploid spermatids into spermatozoa [1]. As a conse-
quence, a large amount of RNAs is synthesized and stored in male
germ cells within ribonucleoprotein particles and granules. The
most peculiar example is provided by the chromatoid body (CB),
a perinuclear, non-membranous, cloud-like structure that closely
resembles the fibrous and dense material named ‘‘germ plasm’’ in
lower organisms [2]. In mouse germ cells, few particles resembling
the CB first appear in the cytoplasm of late pachytene
spermatocytes. After meiosis, the CB condenses to form a single
granule in round spermatids, which can be detected until the
nucleus of the differentiating spermatids begins to elongate [2].
Due to its large size (,0.5 mm), the CB can be easily observed by
phase contrast microscopy and was first described more than
130 years ago in the cytoplasm of rat spermatids [3]. Nevertheless,
its molecular composition and biological function(s) have remained
largely unknown for over a century [2,4,5]. The recent purification
of the CB from mouse germ cells has allowed a more detailed
description of its composition [6]. Analysis of the protein content
by mass spectrometry revealed that the bulk of the CB mass is
composed of six proteins that are involved in different aspects of
RNA processing. They include the RNA helicase DDX4/MVH
(Mouse VASA Homologue), the PIWI protein named PIWIL1/
MIWI, the Tudor domain containing proteins TDRD6 and 7, the
gonadotropin regulated testicular helicase DDX25/GRTH and
the polyA binding protein PABPC3 [6]. Genetic studies revealed
that ablation of Mvh, Miwi, Grth, Tdrd6 and Tdrd7 in mice impairs
spermatogenesis and male fertility [7–11]. Moreover, the CB of
round spermatids in Miwi, Grth, Tdrd6 and Tdrd7 knockout germ
cells exhibits morphological abnormalities [8–12]. Although the
early meiotic arrest of spermatogenesis in Mvh knockout mice
prevented this analysis [7], it is likely that MVH also plays a key
role in CB assembly and function. Thus, the CB seems to function
as an RNA-processing centre in male germ cells, as previously
demonstrated for the germ plasm of lower organisms [2].
Pioneer studies using cell labelling and histochemistry had
already suggested the presence of RNA and ribonucleoproteins in
the CB few decades ago [13,14]. More recent observations have
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confirmed that the CB is a site of accumulation of several classes of
RNAs, such as microRNAs (miRNAs) [15], PIWI-interacting
RNAs (piRNAs) and mRNAs [6]. The finding that polyadenylated
mRNAs accumulate in the CB of spermatids [15] together with
miRNAs and proteins that are essential for mRNA silencing,
further suggests that the CB participates in translational regulation
of specific mRNAs. Interestingly, the CB displays a very dynamic
nature in germ cells [4,16], suggesting that it may collect RNAs
and proteins from the nucleus and function as a control station
where the fate of a given RNA is decided [2]. However, in spite of
its highly dynamic nature, very few proteins have been shown to
transiently localize in the CB at specific stages of spermatogenesis.
One example is provided by the RNA binding protein (RBP)
HuR, which accumulates in the CB of early round spermatids
[17]. In this work, we report that SAM68 transiently localizes in
the CB during the meiotic divisions and in early post-meiotic cells.
SAM68 is a KH-type RBP involved in several steps of RNA
processing in male germ cells, whose function is essential for male
fertility [18]. We previously described that SAM68 regulates the
alternative splicing and translation of specific mRNAs in meiotic
and post-meiotic germ cells [18–20], and that these functions are
necessary for the formation of a functional gamete [18]. We now
found that, although the major protein components of the CB are
correctly recruited in the absence of SAM68, expression of
selected miRNAs is altered in Sam682/2 male germ cells.
Together with the observation that SAM68 interacts with
DROSHA and DICER, these results suggest a novel role for
SAM68 in CB-linked RNA processing events and in the miRNA
pathway during spermatogenesis.
Results
SAM68 localizes in perinuclear granules in secondary
spermatocytes and early round spermatids
SAM68 shuttles between nucleus and cytoplasm in differenti-
ating germ cells [18,20]. To investigate in more detail the dynamic
nature of its localization, we performed immunofluorescence
analysis of purified male germ cells. As previously reported [20],
SAM68 is localized in the nucleus of pachytene spermatocytes, it
translocates into the cytoplasm of secondary spermatocytes and it
localizes again in the nucleus of round spermatids (Figure 1A).
However, we also observed that SAM68 accumulates in peri-
nuclear, dense granules resembling the CB in secondary
spermatocytes and early round spermatids (Figure 1A).
SAM68 was reported to accumulate in cytoplasmic stress
granules upon several cellular stresses [21–23]. To rule out the
possibility that the accumulation of SAM68 in perinuclear
granules is caused by stress occurring during the purification
procedure, we analysed its localization in germ cells squashed out
directly from the seminiferous tubules. This technique allows
precise description of the stage of the seminiferous tubule by phase
contrast microscopy before fixation [24]. We found that SAM68
localized in the cytoplasm and was enriched in perinuclear
granules in meiotic spermatocytes from stage XII tubules and in
early round spermatids from stages XII and I (Figure 1B). By
contrast, starting from late stage I spermatids, SAM68 was
predominantly nuclear and this localization was maintained from
stage II through VIII (Figure 1B).
These results indicate that SAM68 transiently accumulates in
perinuclear granules during the meiotic divisions and the early
phases of spermiogenesis.
SAM68 co-localizes with MVH and MILI in the chromatoid
body of secondary spermatocytes
To test whether the SAM68-containing granule is the CB, we
co-stained purified male germ cells with anti-SAM68 and anti-
MVH antibodies or anti-MILI antibodies. SAM68 and MVH
localize to different compartments in primary spermatocytes and
round spermatids. Namely, SAM68 was found exclusively in the
nucleus of meiotic and post-meiotic cells, whereas MVH
accumulated in perinuclear structures of primary spermatocytes
and in the CB of round spermatids (Figure 2A). However, in
secondary spermatocytes a fraction of SAM68 accumulated in the
CB-like granules together with MVH (Figure 2A). Similar results
were obtained by comparing the localization of SAM68 with that
of MILI [25]. As shown in Figure 2B, MILI localized to fibrous,
perinuclear structures in primary spermatocytes and in CB-like
perinuclear granules that also contained SAM68 in secondary
spermatocytes. By contrast, MILI was absent in the majority of
round spermatids whereas SAM68 was localized in the nucleus.
These results strongly suggest that SAM68 transiently accumulates
in the granules that will form the CB during the second meiotic
division and in early round spermatids.
To corroborate the association of SAM68 with CB components,
we performed immunoprecipitation experiments from purified
germ cells. Extracts obtained from a germ cell fraction enriched in
secondary spermatocytes [20] were immunoprecipitated with anti-
SAM68 or control antibodies. Western blot analysis revealed that
MVH was co-immunoprecipitated with the anti-SAM68, but not
with control IgGs (Figure 3A). Importantly, co-immunoprecipita-
tion was due to a specific interaction in the dividing meiotic germ
cells, as it was not detected in primary spermatocytes and round
spermatids (Figure 3B), in which the two proteins localize in
different cellular compartments (Figure 2A).
Structural proteins of the chromatoid body are not
affected by the ablation of Sam68
To further investigate the role of SAM68 in the CB, we
subjected sections of Sam68 wild-type and knockout testes to high-
resolution morphological analysis by transmission electron mi-
croscopy (EM). We found that the CBs in Sam682/2 late round
spermatids (steps 6–8) were often smaller and/or appeared
incorrectly assembled (Figure 4E, F) as compared to those of wild
type germ cells, which are characterized by large and dense masses
with many clear islands (Figure 4B). However, in some Sam682/2
late round spermatids the CB appeared normal (Figure 4D).
Furthermore, in early round spermatids (steps 1–3), the CBs
appeared mostly unaffected (Figure 4A, C).
Since the Sam68 knockout testis is characterized by abnormal
differentiation and extensive loss of haploid germ cells [18], the
impaired morphology of the CB could be a secondary, indirect
effect. To test this hypothesis, we checked whether any CB
structural component was lacking in the Sam68 knockout
spermatids. First, we determined the localization of MVH by
immunofluorescence analysis of wild type and knockout secondary
spermatocytes and early round spermatids. As shown in Figure 5A,
the absence of SAM68 did not impair MVH localization in the
CB. In addition, we also found that ablation of MIWI,
a constitutive component of the CB [6], did not impair the
localization of SAM68 in the CB (Figure 5B).
Next, to obtain a comprehensive picture of the CB in Sam682/2
germ cells, we used a recently developed method to isolate the CB
by immunoprecipitation of MVH after crosslinking and lysis of
testicular germ cells [6]. The CB isolation protocol is schematically
represented in Figure 6A. All the steps of the immunoprecipitation
Sam68 and miRNA Pathway
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Figure 1. SAM68 accumulates in a perinuclear organelle in secondary spermatocytes and early round spermatids. (A) Purified male
germ cells were stained with an anti-SAM68 antibody (red) and co-stained with Hoechst (blue) to detect nuclei and to identify cell stages by nuclear
morphology. In secondary spermatocytes and early round spermatids SAM68 accumulates into a granule (white arrows) resembling the chromatoid
body. (B) Stage specific localization of SAM68 during spermatogenesis. Squashes of male germ cells from seminiferous tubules at different stages of
spermatogenesis show that SAM68 (red) localizes in the cytoplasm and was enriched in perinuclear granules (arrows) in meiotic spermatocytes from
stage XII tubules and in early round spermatids from stages XII and I (A–E). In late stage I spermatids and from stage II through VIII, SAM68 was
predominantly nuclear (F–L). Cells were co-stained with DAPI to detect nuclei. 2nd = secondary spermatocytes; RS = round spermatid; PSpc =
pachytene spermatocyte; ES = elongated spermatid.
doi:10.1371/journal.pone.0039729.g001
Sam68 and miRNA Pathway
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were monitored by immunofluorescence analysis with the CB-
specific anti-MVH antibody, which detected a CB-associated
granular signal in the pellet fractions (PEL and P2F) (Figure 6B),
but not in the supernatant fractions (data not shown). As
previously reported [18], the number of round spermatids in the
knockout testes was lower than in the wild type testes, thus the
isolation yielded less CBs. This is evident from the much weaker
MVH signal observed by Western blot analysis in the CB extracts
of the knockout samples (Figure 6C). Poly(A)-containing RNAs
and small regulatory RNAs such as piRNAs are known to
accumulate in the CB [6]. To visualize the small RNA species
present in the CBs, total RNA extracted from the control and
knockout fractions were 5’-labeled with [c-32P]ATP and separat-
ed on a 15% denaturing polyacrylamide gel. This analysis showed
that the Sam682/2 CBs contained the characteristic ,30
nucleotide (nt) piRNA band (Figure 6D), although in lower
quantities probably due to the lower yield of CBs obtained from
the knockout sample.
The purified CBs from wild type and knockout germ cells were
then subjected to analysis by mass spectrometry. The main
constituents of the CB are MVH, MIWI, TDRD6, TDRD7,
GRTH and PABPC3 [6]. In particular, four of these proteins
(MIWI, GRTH, TDRD6 and TDRD7) are essential in the
maintenance of the normal architecture of the CB [2]. All the
main components including the Tudor-domain containing pro-
teins (TDRD1, TDRD6, TDRD7), DEAD box helicases (DDX25
and MVH), poly(A)-containing proteins (PABPC1), PIWI proteins
(MIWI and MILI) and other proteins associated with piRNA
pathways (MAEL) were present in the knockout CBs (Figure 6E).
In agreement with the immunofluorescence results, SAM68 was
found in the control CBs but not in the knockout CBs. Some less
abundant CB proteins present in the control samples were missing
from the Sam682/2 CBs (data not shown). However, since the
Figure 2. Co-localization of SAM68 with MVH and MILI in male germ cells. (A) Isolated male germ cells were co-stained with an anti-SAM68
antibody (red), an anti-MVH antibody (green) and with Hoechst (blue) to detect nuclei. SAM68 and MVH partially co-localize in the CB of secondary
spermatocytes (arrows), while in primary spermatocytes SAM68 is nuclear and MVH is cytoplasmic, and in round spermatids SAM68 is nuclear and
MVH is predominantly localized in the CB. (B) Isolated germ cells were analysed by immunofluorescence using the anti-SAM68 antibody (red) and the
anti-MILI antibody (green). Nuclei were stained with Hoechst (blue) to identify cell stages by nuclear morphology. In primary spermatocytes SAM68
localizes in the nucleus, while MILI is cytoplasmic; in round spermatids SAM68 is nuclear and MILI is absent. The localization of the two proteins
partially overlaps only in the CB of secondary spermatocytes.
doi:10.1371/journal.pone.0039729.g002
Figure 3. SAM68 co-immunoprecipitates with MVH in second-
ary spermatocytes. (A) Total extract from secondary spermatocytes
were immunoprecipitated with an anti-SAM68 antibody and analysed in
Westeern blot with anti-MVH and anti-Sam68 antibodies. (B) Cellular
extracts from spermatocytes (I sp.cytes), secondary spermatocytes (II
sp.cytes) and round spermatids (sp.tids) were immunoprecipitated with
an anti-SAM68 antibody and detected with anti-MVH antibody. Western
blot analysis shows a specific interaction of the two proteins in
secondary spermatocytes, while no signal is detected in other germ cell
populations.
doi:10.1371/journal.pone.0039729.g003
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Sam682/2 CB samples were less concentrated, it is likely that less
abundant CB components could not be identified reliably.
These results suggest that SAM68 expression is not essential for
the CB structure.
SAM68 ablation affects the expression of a subset of
microRNAs in male germ cells
In addition to PIWI proteins and piRNAs, the CB was also
shown to contain miRNAs and proteins involved in the miRNA
maturation pathway [15]. Notably, recent studies have documen-
ted a role of splicing factors in the biogenesis of selected miRNAs
[26–29]. To investigate the possible involvement of SAM68, a well
known splicing regulator [30], in miRNA biogenesis, we first tested
its association with key proteins in the pathway. All miRNAs are
initially transcribed as primary transcripts that are successively
cleaved by two RNase III enzymes, DROSHA in the nucleus and
DICER in the cytoplasm, to produce ,70 nt long precursor
miRNAs and 22 nt long mature miRNAs, respectively [31]. Co-
immunoprecipitation experiments indicated that SAM68 interacts
with both DICER (Figure 7A) and DROSHA (Figure 7B) in male
germ cells. These interaction were not disrupted by treatment with
RNase, indicating that they were not mediated by a bridging RNA
(Fig. 7C). These results suggest that SAM68 may participate to
miRNA biogenesis. To test this hypothesis, we performed
a microarray analysis of miRNAs purified from wild type and
knockout primary spermatocytes, secondary spermatocytes and
round spermatids (Figure 7D). Hybridization of the purified RNAs
to the miRCURY LNA microarray revealed that Sam68 ablation
selectively affected 12 miRNAs, the majority of which (9 out of 12)
were upregulated in knockout germ cells (Figure 7D). Interestingly,
with the exception of miR-138, all these miRNAs were differen-
tially expressed at stages that are concomitant (secondary
spermatocytes) or subsequent (round spermatids) to the association
of SAM68 with the CB (Figure 7D). To validate the results of the
array, we analyzed the expression of three of these miRNAs (miR-
720, miR-142-3p and miR-29b) by quantitative real time PCR. As
shown in Figure 7E, all of them were upregulated in Sam682/2
germ cells with respect to the corresponding wild type cells.
Figure 4. Morphology of the chromatoid body in Sam682/2 germ cells. (A, B) Round spermatids were analyzed by electron microscopy to
study the possible changes in the morphology of the CB caused by the deletion of Sam68 gene. No differences were found between the early
chromatoid bodies (steps 1–3 of round spermatid differentiation) in the control (A) and knockout (C) testes. The knockout CBs appeared condensed
and morphologically normal. In late round spermatids (steps 6–8), the knockout CBs appeared mostly normal (D) as compared to the control CBs (B).
Abnormalities in the CB morphology were also commonly observed in Sam682/2 late round spermatids, such as decreased amount of the
chromatoid material (E) or excess space between the CB lobes (F). Arrows point to the CB. Acrosome is indicated by an asterisk. The genotypes and
the steps of spermatid differentiation are shown in the upper right corner of each image. WT, Sam68+/+; KO, Sam682/2; Nu, nucleus. Scale bar is 2 mm.
doi:10.1371/journal.pone.0039729.g004
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These results suggest that SAM68 is involved in the miRNA
pathway of male germ cells.
Discussion
The molecular nature and the function of the CB in germ cells
have remained elusive and debated for years [2,4,5,32]. Recently,
the demonstration that many RBPs and RNA species associate
with this structure, has lead to the general consensus that the CB
functions as an RNA-processing centre [2,5]. The CB material
appears in late pachytene spermatocytes and it fuses together to
mould into a single structure in each round spermatid after meiosis
[2–4,32,33]. During spermiogenesis, the CB increases in size until
step 6, then it moves caudally to the neck region and gradually
decreases in size until it disappears in elongating spermatids
[5,14,33,34]. Furthermore, the CB dynamically moves within the
cytoplasm and exhibits continuous changes in shape and size
[4,14]. Nevertheless, very few examples of proteins that transiently
associate with the CB have been reported [2,16]. In the present
study we demonstrate that SAM68 is one of such proteins, which
transiently associates with the CB of secondary spermatocytes and
early round spermatids.
SAM68 is a ubiquitously expressed KH-type RBP, whose
expression levels and localization vary during cell differentiation in
several tissues [35]. In particular, in male germ cells SAM68 is
mainly nuclear, but it translocates into the cytoplasm of secondary
spermatocytes, where it regulates the translation of specific mRNA
targets [18,20]. This function of the protein is essential for the
production of a functional gamete, as Sam682/2 haploid germ
cells express lower levels of a subset of proteins involved in cell
differentiation, display abnormal morphology and undergo
massive cell death through apoptotic pathways [18]. We have
now observed that during its translocation in the cytoplasm,
SAM68 accumulates in perinuclear structures. Co-staining anal-
ysis with both anti-MVH and anti-MILI antibodies confirmed that
these granules correspond to the forming CB in meiotic and post-
meiotic male germ cells. However, SAM68 expression does not
seem to be required for CB assembly and structure. Our EM
analysis showed that the CB of Sam682/2 early round spermatids
(step-2–3) is normal. In late round spermatids (steps 6–8) from
knockout testes we often observed smaller and/or incorrectly
assembled CBs as compared to those of wild type germ cells.
Nevertheless, it is likely that these abnormalities are indirect
consequences of the morphological and molecular defects occur-
ring in Sam682/2 haploid germ cells, which ultimately lead to
apoptosis (18). This interpretation is also supported by our mass
spectrometry analysis of purified CBs. We found that, although
less material was obtained from Sam682/2 testes, the main CB
protein constituents were all correctly recruited in the absence of
SAM68. This unbiased analysis also confirmed that SAM68 was
present in the CB purified from wild type germ cells, thus
corroborating the immunofluorescence results. Our study also
showed that some of the less abundant CB proteins were absent in
the CBs of knockout samples, whereas piRNAs were present in
lower amounts. However, since a general lower yield in CB
material was obtained from the knockout germ cells, we suggest
Figure 5. Localization of MVH and SAM68 in the chromatoid body of Sam68 and Miwi knockout germ cells. (A) Immunofluorescence
analysis with anti-MVH (upper panels) or anti-SAM68 (bottom panels) antibodies of Sam68 wild type (left panels) and knockout (right panels) male
germ cells. Nuclei were detected with Hoechst (blue). (B) Immunofluorescence analysis with anti-SAM68 (red) and anti-DDX25 (green) antibodies of
Miwi knockout (right panels) male germ cells. Nuclei were detected with Hoechst (blue).
doi:10.1371/journal.pone.0039729.g005
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that these differences are mainly attributable to the lower
concentration of these proteins than to their selective differential
recruitment.
Several reports have recently linked the CB to components of
the miRNA pathway [2]. First, it was shown that DICER, AGO2,
AGO3 and some miRNAs were enriched in the CB of round
spermatids [15]. Furthermore, ablation of expression of TDRD6,
a CB architectural protein, affected the expression of several
miRNAs in the testis, suggesting that TDRD6 is involved in the
miRNA pathway [10]. More recently, the RNA DEAD-box
helicase GEMIN3 (DDX20), a microRNA biogenesis factor, was
shown to accumulate in the CB of human and mouse germ cells
[36]. On the other hand, many RBPs that play key role in pre-
mRNA splicing, like SAM68, have been recently reported to
participate to various steps in the processing of miRNAs [26–29].
Thus, we directly investigated whether SAM68 is involved in
miRNA biogenesis in male germ cells. Indeed, we found that
SAM68 interacts with DROSHA and DICER, the two RNase III
enzymes involved in the nuclear and cytoplasmic processing of the
miRNA precursors [31]. The contribution of Sam68 in the
processing of miRNAs was also supported by the changes in
selected miRNAs observed in Sam682/2 male germ cells. Twelve
miRNAs were differentially expressed between wild-type and
knockout germ cells. The majority of them were up-regulated,
Figure 6. Isolation and analysis of chromatoid bodies from male germ cells. (A) Schematic representation of the CB isolation protocol. (B)
Immunofluorescence analysis of different steps of CB immunoprecipitation experiment, comparing Sam68 wild type (WT) and knockout (KO) extracts.
Cells were stained with an anti-MVH antibody (red) and with Hoechst to detect nuclei. CELLS = cells before lysis; LYS = lysate; PEL = pellet fraction;
P2F = pellet fraction after filtration. (C) Immunoblotting of the CB extracts with anti-MVH antibody to validate the success of the purification. The less
intensive signal in the knockout CB fraction indicates the lower number of CBs isolated from the knockout testes compared to the control. anti-ACR,
negative control IP; anti-MVH, CB IP. (D) RNA gel to demonstrate the presence of piRNAs. Total RNA was extracted from the the lysate (LYS) and CB IPs
(CB), radiolabelled and run into a polyacrylamide gel in. (E) Mascot analysis of the main CB components. All major CB proteins were present in the
knockout CBs. The uniprot entry name KDHR_MOUSE equals to SAM68.
doi:10.1371/journal.pone.0039729.g006
Figure 7. SAM68 is involved in the miRNA pathway in male germ cells. (A) Total extract from secondary spermatocytes were
immunoprecipitated with an anti-SAM68 antibody and analysed in Western blot with anti-DICER and anti-Sam68 antibodies. (B) Cellular extracts from
secondary spermatocytes (II sp.cytes) were immunoprecipitated with an anti-DROSHA antibody and detected with anti-DROSHA, anti-SAM68 and
anti-hnRNP A1 antibodies. (C) Western blot analysis of co-immunoprecipitation performed in the presence of RNase in the cell extract. (D) Schematic
representation of the microRNAs differentially expressed in the indicated Sam68 knockout germ cells. In green are indicated the down-regulated
microRNAs, in red the up-regulated ones. The immunofluorescence images show the localization of SAM68 in the corresponding wild type germ cells.
(E) Real Time PCR analysis of miR-720, miR-142-3p and miR-29b in RNA purified from round spermatids of Sam68 wild-type (black) or knockout (grey)
mice. The values were normalized against U6 snRNA and expressed as fold increase with respect to the value of wild type cells.
doi:10.1371/journal.pone.0039729.g007
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whereas only three miRNAs were down-regulated in Sam682/2
germ cells. Notably, a similar increase of more than 50 miRNAs
was also observed in Tdrd6 knockout testis [10], suggesting that
SAM68 may play a similar role in this pathway. The function of
most of the SAM68-modulated miRNAs is largely unknown.
However, miR-29b was previously proposed to play a role in the
modulation of genomic DNA methylation in female primordial
germ cells, by negatively regulating the expression DNMT3a and
DNMT3b [37]. Notably, miR-29b belongs to a family of miRNAs
that are often down-regulated in human cancers, including
hormone-resistant prostate cancer (PCa) [38,39], and increased
ectopic expression of miR-29b suppressed the metastatic pheno-
type of PCa cells by repressing epithelial-mesenchymal transition
(EMT) signalling [39]. Since SAM68 is frequently up-regulated in
PCa, where it contributes to cell proliferation and survival [40,41],
these observations suggest that it might regulate miR-29b also in
cancer cells. In line with this hypothesis, recent observations
indicate that SAM68 contributes to oncogenic transformation by
promoting EMT [42]. Thus, it is possible that increased expression
of SAM68 in PCa cells is required to suppress miR-29b expression,
hence contributing to the aggressive phenotype of these cells.
The expression of miRNAs can be regulated at the post-
transcriptional level by modulating nuclear and cytoplasmic
processing events. For instance, the KH-type splicing regulatory
protein KSRP binds to the terminal loop of its target miRNAs,
thereby promoting their processing [28]. The function of KSRP is
antagonized by another splicing factor: hnRNP A1. It was shown
that hnRNP A1 competes with KSRP for binding to the conserved
terminal loop of pri-let-7a-1 and inhibits its processing by
DROSHA [27]. Interestingly, hnRNP A1 interacts with
DROSHA [26] and with SAM68 [43] in somatic cells, and we
found that these three proteins can be co-immunoprecipitated
together in male germ cell extracts (Figure 7B). Noteworthy,
SAM68 and hnRNP A1 cooperate in the regulation of splicing of
at least two common targets [43,44]. Thus, although direct studies
to test this possibility need to be performed in the near future, it is
tempting to speculate that SAM68 participates to hnRNP A1-
mediated processing of selected miRNAs.
In conclusion, our study identifies SAM68 as a novel CB
component that transiently associates with this structure and
provide evidence for the involvement of SAM68 in the miRNA
pathway during spermatogenesis.
Materials and Methods
Cell isolation and culture
The Sam68 knockout colony was maintained by crossing Sam68
heterozygous mice. Genotyping of the mice was performed as
described previously [45]. Testes from 40–60 day-old CD1 mice
(Charles River Laboratories) and C57BL6 Sam68 wild-type and
knockout mice were used to obtain pachytene spermatocytes,
secondary spermatocytes, and round spermatids by elutriation
technique as described previously [20,46]. After elutriation,
pachytene spermatocytes were cultured in minimum essential
medium (Invitrogen) and supplemented with 0.5% BSA (Sigma-
Aldrich), 1 mM sodium pyruvate, and 2 mM lactate at 32uC in
a humidified atmosphere containing 95% air and 5% CO2. At the
end of the incubation, cells were washed in phosphate buffered
saline (PBS) and used for further experiments.
Immunofluorescence analysis
Mouse germ cells were fixed in 4% paraformaldehyde (PFA)
and washed three times in PBS. Cells were permeabilized with
0.1% Triton X-100 (Sigma-Aldrich) for 10 min and then
incubated for 1 h in 0.5% BSA. Cells were washed three times
in PBS and incubated for 2 h at room temperature (RT) with
antibodies against SAM8 (1:1000, Santa Cruz Biotechnology),
MVH (1:500; Abcam) or MILI (1:200, Abcam), followed by 1 h
incubation with cy3-conjugated anti-mouse IgGs (Alexa Fluor) or
FITC-conjugated anti-rabbit IgGs (Alexa Fluor). After washes,
slides were mounted with Mowiol reagent (EMD) and analyzed by
microscopy at RT as described [22,47]. Images were taken from
a fluorescent microscope (Axioskop; Carl Zeiss, Inc.) using a Pan-
Neofluar 406/0.75 objective lens, and from an inverted micro-
scope (DMI6000B; Leica) using a Pan-Neofluar 406/0.75
objective lens. Images were acquired as TIFF files using an RT
slider camera (Diagnostic Instruments) and the IAS2000 software
(Biosistem 82) or LIF software (Leica). Photoshop and Illustrator
softwares (Adobe) were used for composing the panels.
Immunoprecipitation experiments
Isolated mouse germ cells were washed in PBS and homoge-
nized in lysis buffer [100 mM NaCl, 10 mM MgCl2, 30 mM Tris-
HCl, pH 7.4, 1 mM DTT, and protease inhibitor cocktail (Sigma-
Aldrich)] supplemented with 0.5% Triton X-100. Soluble extracts
were separated by centrifugation at 10000 g for 10 min, pre-
cleared for 2 h on protein A–Sepharose beads (Sigma-Aldrich) in
the presence of rabbit IgGs (5 mg) and 0.05% BSA. After
centrifugation for 1 min at 1000 g, supernatant fractions were
incubated with rabbit anti-SAM68, anti-DROSHA (Abcam) or
control IgGs (5 mg) for 3 h at 4uC under constant rotation. After
washing, the beads were eluted in SDS sample buffer for Western
blot analysis with anti-MVH antibody (1:500).
Chromatoid body immunoprecipitation
Testes from adult C57BL6 Sam68 wild-type and knockout mice
were digested in PBS containing 0.5 mg/ml of collagenase for
60 minutes at room temperature. Digested tubules were filtered
through 100 mm filter (BD biosciences) and then centrifuged for
5 minutes at 300 g, 4uC. After two washes in PBS, cells were
crosslinked in 0.1% PFA for 20 min. The reaction was stopped by
adding 0.25 M glycine, pH 7. Cells were washed in PBS,
resuspended in RIPA buffer [150 mM NaCl, 50 mM Tris-HCl,
pH 7.5, 1 mM DTT, 1% Nonidet P40, 0.5% sodium deoxycho-
late, 1:200 Riboblock (Fermentas) and protease inhibitor cocktail
(Roche)] and sonicated with Bioruptor UCD-200 sonicator (6
cycles of 30 s with 30 s intervals). The cell lysate was centrifuged
for 10 minutes at 500 g. The pellet containing the CBs was filtered
and resuspended in RIPA buffer and used for immunoprecipita-
tion [6]. Cell lysates were pre-cleared with Dynabeads protein G
(Invitrogen) for 30 minutes, and then added to Dynabeads protein
G coupled with rabbit polyclonal anti-MVH antibody (Abcam,
ab13840) or rabbit-polyclonal anti-ACROSIN (Santa Cruz, sc-
67151) antibody. Tubes were incubated overnight at 4uC under
rotation. Beads were rinsed, resuspended in RIPA buffer and the
crosslinks were reversed in the same buffer (for RNA analysis) or in
SDS sample buffer (for protein analysis) at 70uC for 45 minutes.
Electron microscopy
Small pieces of testis were cut, fixed in 5% glutaraldehyde and
treated with a potassium ferrocyanide-osmium fixative. The
samples were embedded in epoxy resin (Glycidether 100, Merck),
sectioned, stained with 5% uranyl acetate and 5% lead citrate, and
visualized on a JEOL 1200 EX transmission electron microscope.
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Mass spectrometric analysis
Proteins were shortly separated with NuPAGE Novex Gel
System (Invitrogen) followed by in-gel digestion with Trypsin
(Promega) and the extraction of peptides. The peptides were
analyzed with LC-MS/MS using an Agilent 1200 series nanoflow
system (Agilent Technologies) connected to a LTQ Orbitrap mass-
spectrometer (Thermo Electron, San Jose, CA, USA) equipped
with a nanoelectrospray ion source (Proxeon, Odense, Denmark).
Microarray analysis
RNA from isolated male germ cells (spermatocytes, secondary
spermatocytes and round spermatids) from adult Sam68+/+ (n = 4)
and Sam682/2 (n = 4) mice was extracted kit (QIAGEN). RNA
samples were tagged for labeling with Cy3 and Cy5 dyes,
respectively using QIAzol lysis reagent and the MIRNeasy mini,
by using the miRCURY Labeling Kit (Exiqon) for use with Exiqon
miRCURY LNA Array (v 10.0). The array consists of probes for
the mature forms of all miRNA present in the miRBase 14.0
release of the miRNA registry. Probes corresponds to 1891 mature
miRNAs, each represented twice on the microarray. The locked-
nucleic acid miRNA probes are highly sensitive and optimized to
minimize cross-hybridization between similar mature miRNAs.
Two biological replicates for each sample were analysed. For each
sample, 4 mg of total RNA was labeled and hybridized to the
microarray. Sample RNA quality control was performed using
Bioanalyser2100. Microarray data were normalized using the
global Lowess (Locally Weighted Scatterplot Smoothing) re-
gression algorithm (Exiqon).
Real time PCR
Validation of selected miRNA expression levels was performed
using the TaqmanH miRNA Expression Assays (Applied Biosys-
tem). RNA was reverse-transcribed using specific miRNA stem-
loop primers and the TaqmanH miRNA reverse transcription kit
(Applied Biosystems). Mature miRNA expression was measured
with TaqmanH microRNA assays (Applied Biosystems) according
to the manufacturer’s instructions and normalized for the
expression level of the snRNP U6 RNA.
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